

INTERNATIONAL LAW JOURNAL

WHITE BLACK LEGAL LAW JOURNAL

ISSN: 2581-8503

Peer - Reviewed & Refereed Journal

The Law Journal strives to provide a platform for discussion of International as well as National Developments in the Field of Law.

WWW.WHITEBLACKLEGAL.CO.IN

DISCLAIMER

EDITORIAL TEAM

Raju Narayana Swamy (IAS) Indian Administrative Service officer

Dr. Raju Narayana Swamy popularly known as Kerala's Anti Corruption Crusader is the All India Topper of the 1991 batch of the IAS and is currently posted as Principal Secretary to the Government of Kerala . He has earned many accolades as he hit against the political-bureaucrat corruption nexus in India. Dr Swamy holds a B.Tech in Computer Science and Engineering from the IIT Madras and a Ph. D. in Cyber Law from Gujarat National Law University . He also has an LLM (Pro) (with specialization in IPR) as well as three PG Diplomas from the National Law University, Delhi- one in Urban Environmental Management and Law, another in Environmental Law and Policy and a third one in Tourism and Environmental Law. He also holds a post-graduate diploma in IPR from the National Law School, Bengaluru and a professional diploma in Public Procurement from the World Bank.

Dr. R. K. Upadhyay

Dr. R. K. Upadhyay is Registrar, University of Kota (Raj.), Dr Upadhyay obtained LLB , LLM degrees from Banaras Hindu University & Phd from university of Kota.He has succesfully completed UGC sponsored M.R.P for the work in the ares of the various prisoners reforms in the state of the Rajasthan.

Senior Editor

Dr. Neha Mishra

Dr. Neha Mishra is Associate Professor & Associate Dean (Scholarships) in Jindal Global Law School, OP Jindal Global University. She was awarded both her PhD degree and Associate Professor & Associate Dean M.A.; LL.B. (University of Delhi); LL.M.; Ph.D. (NLSIU, Bangalore) LLM from National Law School of India University, Bengaluru; she did her LL.B. from Faculty of Law, Delhi University as well as M.A. and B.A. from Hindu College and DCAC from DU respectively. Neha has been a Visiting Fellow, School of Social Work, Michigan State University, 2016 and invited speaker Panelist at Global Conference, Whitney R. Harris World Law Institute, Washington University in St.Louis, 2015.

Ms. Sumiti Ahuja

Ms. Sumiti Ahuja, Assistant Professor, Faculty of Law, University of Delhi,

Ms. Sumiti Ahuja completed her LL.M. from the Indian Law Institute with specialization in Criminal Law and Corporate Law, and has over nine years of teaching experience. She has done her LL.B. from the Faculty of Law, University of Delhi. She is currently pursuing Ph.D. in the area of Forensics and Law. Prior to joining the teaching profession, she has worked as Research Assistant for projects funded by different agencies of Govt. of India. She has developed various audio-video teaching modules under UGC e-PG Pathshala programme in the area of Criminology, under the aegis of an MHRD Project. Her areas of interest are Criminal Law, Law of Evidence, Interpretation of Statutes, and Clinical Legal Education.

Dr. Navtika Singh Nautiyal

Dr. Navtika Singh Nautiyal presently working as an Assistant Professor in School of law, Forensic Justice and Policy studies at National Forensic Sciences University, Gandhinagar, Gujarat. She has 9 years of Teaching and Research Experience. She has completed her Philosophy of Doctorate in ‘Intercountry adoption laws from Uttranchal University, Dehradun’ and LLM from Indian Law Institute, New Delhi.

Dr. Rinu Saraswat

Associate Professor at School of Law, Apex University, Jaipur, M.A, LL.M, Ph.D,

Dr. Rinu have 5 yrs of teaching experience in renowned institutions like Jagannath University and Apex University. Participated in more than 20 national and international seminars and conferences and 5 workshops and training programmes.

Dr. Nitesh Saraswat

E.MBA, LL.M, Ph.D, PGDSAPM
Currently working as Assistant Professor at Law Centre II, Faculty of Law, University of Delhi. Dr. Nitesh have 14 years of Teaching, Administrative and research experience in Renowned Institutions like Amity University, Tata Institute of Social Sciences, Jai Narain Vyas University Jodhpur, Jagannath University and Nirma University.
More than 25 Publications in renowned National and International Journals and has authored a Text book on Cr.P.C and Juvenile Delinquency law.

Subhrajit Chanda

BBA. LL.B. (Hons.) (Amity University, Rajasthan); LL. M. (UPES, Dehradun) (Nottingham Trent University, UK); Ph.D. Candidate (G.D. Goenka University)

Subhrajit did his LL.M. in Sports Law, from Nottingham Trent University of United Kingdoms, with international scholarship provided by university; he has also completed another LL.M. in Energy Law from University of Petroleum and Energy Studies, India. He did his B.B.A.LL.B. (Hons.) focussing on International Trade Law.

ABOUT US

WHITE BLACK LEGAL is an open access, peer-reviewed and refereed journal providededicated to express views on topical legal issues, thereby generating a cross current of ideas on emerging matters. This platform shall also ignite the initiative and desire of young law students to contribute in the field of law. The erudite response of legal luminaries shall be solicited to enable readers to explore challenges that lie before law makers, lawyers and the society at large, in the event of the ever changing social, economic and technological scenario.

With this thought, we hereby present to you

CHALLENGES IN HARMONISING INDIAN PATENT ACT WITH PATENT COOPERATION TREATY (PCT) - A CRITICAL STUDY

AUTHORED BY – SWARNIKA

ABSTRACT

The harmonization of the Indian Patent Act with the Patent Cooperation Treaty (PCT) presents a complex set of challenges, rooted in the balance between national interests and global intellectual property norms. The Indian Patent Act, with its emphasis on safeguarding public health and promoting indigenous innovation, often contrasts with the broader objectives of the PCT, which is designed to streamline patent procedures and encourage international cooperation. While India is a signatory to the PCT and allows applicants to file international patent applications through the treaty's mechanism, the alignment of substantive patent laws remains limited. One of the core challenges lies in India's approach to patentability, particularly concerning pharmaceuticals and software. Provisions such as Section 3(d) of the Indian Patent Act prevent the granting of patents for minor modifications of existing drugs, which is inconsistent with more lenient patentability criteria followed in many PCT member countries.Furthermore, procedural disparities also pose obstacles. India's patent examination process, timelines, and documentation requirements do not always align with the standards set by the PCT, causing friction for applicants seeking seamless protection across jurisdictions. Another significant challenge is the infrastructural and administrative capacity required to process international applications effectively within the framework of the PCT. India must continually upgrade its patent office capabilities to meet global expectations, which demands considerable investment and policy reform. Additionally, there is resistance from various stakeholders within India who are concerned about the potential erosion of national sovereignty and the prioritization of foreign corporate interests over domestic needs. These concerns make it difficult to fully integrate PCT norms without compromising the developmental and public welfare goals embedded in Indian patent law. Thus, harmonizing the Indian Patent Act with the PCT is not merely a legal or technical issue but a socio-political endeavor requiring careful navigation of competing priorities and international obligations.

CHAPTER 1: INTRODUCTION

The Indian patent system has a rich historical lineage dating back to the colonial period, evolving significantly over time in response to both domestic demands and international developments. The earliest traceable legislation related to patents in India is the Act VI of 1856, modeled after the British Patent Law of 1852, which was intended to encourage inventors to disclose innovations in exchange for exclusive rights (Ghosh, 2014). Over the decades, India witnessed numerous changes in its patent law, culminating in the Patents Act of 1970, which came into force in 1972. This Act replaced all previous laws and laid down the modern foundation of India's patent framework. Unlike the earlier regime, the 1970 Act emphasized the need to safeguard national interest, particularly in critical sectors like pharmaceuticals, by allowing only process patents and excluding product patents (Kumar & Rai, 2007). This approach was driven by the socio-economic realities of India, where access to affordable medicines and technologies was prioritized over corporate monopolies.[1]

India's stance towards patents remained protectionist and welfare-driven for several decades, reflecting a strong desire to stimulate local manufacturing and self-reliance. The patent regime was largely closed to foreign players, especially in sectors like agriculture and health (Basheer & Reddy, 2007). However, with the economic liberalization of the 1990s and India's entry into the World Trade Organization (WTO) in 1995, the need for a comprehensive overhaul of the patent law became inevitable. As part of its commitments under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, India was compelled to strengthen its intellectual property regime (Correa, 2002). Consequently, a series of amendments to the Patents Act were made in 1999, 2002, and 2005 to bring the Indian system in line with global standards. The 2005 amendment was particularly crucial, as it reintroduced product patents in areas such as pharmaceuticals and agrochemicals, thereby aligning India's patent system with TRIPS obligations (Chaudhuri, 2005).

[1] Kumar, N., & Rai, K. R. (2007). *Changing perspectives on innovation and IPR in India*. Technological Forecasting and Social Change, 74(6), 709–728.

Parallel to these changes, India's association with the Patent Cooperation Treaty (PCT) also became significant. The PCT, established in 1970 and administered by the World Intellectual Property Organization (WIPO), is an international treaty designed to simplify the process of filing patents in multiple countries (WIPO, 2023). It allows inventors and companies to file a single "international" patent application which has the same effect as filing separate applications in the designated PCT member countries. This mechanism provides a streamlined process for seeking patent protection across jurisdictions, delaying the need for national phase entries and enabling better decision-making based on preliminary search and examination reports.

India became a member of the PCT on December 7, 1998, and the treaty came into force for the country on December 7, 1998 (WIPO, 2023). The inclusion in the PCT framework marked a pivotal moment in India's engagement with international patent law. The primary objective of India's participation in the PCT was to foster innovation, encourage foreign direct investment, and ensure that Indian inventors had access to the global patenting system (Rai, 2009). By joining the PCT, India offered its citizens an opportunity to file international patent applications through a single window, thereby reducing procedural complexity and costs associated with multiple filings. It also allowed foreign applicants to seek patent protection in India via the PCT route, thus opening up the Indian market to global innovators.

Despite becoming a PCT member and amending domestic laws to comply with TRIPS, India continued to maintain distinct features in its patent regime to address local socio-economic needs. One of the most notable features is Section 3(d) of the Patents Act, which restricts the patentability of new forms of known substances unless they demonstrate significantly enhanced efficacy (Novartis AG v. Union of India, 2013). This provision, though criticized by multinational pharmaceutical companies, has been defended as a tool to prevent evergreening of patents and ensure access to affordable medicines (Basheer, 2012). India's patent law also includes provisions for compulsory licensing, which permits the government to authorize the production of a patented product without the consent of the patent holder under specific conditions such as public health emergencies or failure to make the product available at a reasonable price (Feroz Ali, 2011).[2]

[2] Basheer, S. (2012). India's patent policy: An overview of pharmaceutical patentability and access to medicines. Indian Journal of Law and Technology, 8(1), 15–31.

The co-existence of India's domestic patent policies and its international obligations under the PCT framework gives rise to a complex dynamic. While the PCT focuses on procedural harmonization and easing international patent filings, it does not impose uniform substantive standards for patentability (WIPO, 2023). This gives member states like India some flexibility to maintain national laws that reflect their socio-economic priorities. However, challenges emerge when there is a significant divergence between the expectations of foreign applicants, accustomed to lenient patent regimes, and the strict scrutiny applied by the Indian Patent Office. These issues are particularly prominent in sectors such as pharmaceuticals, software, and biotechnology, where India's laws are often more restrictive than those of other PCT countries (Chaudhuri, 2012).

India's integration into the global patent system through the PCT also required considerable infrastructural and administrative changes. The Indian Patent Office had to upgrade its capabilities to handle international search and examination tasks, enhance its information technology systems, and train its staff to process PCT applications effectively (Kumar, 2010). Over the years, India has made substantial progress in this regard, becoming a competent International Searching Authority (ISA) and International Preliminary Examining Authority (IPEA) under the PCT framework. These roles allow India not only to conduct patent searches for international applications but also to influence global patent trends through its examination reports (WIPO, 2023).

Yet, several bottlenecks remain. The harmonization of India's patent system with the PCT has been gradual and cautious, reflecting the tension between globalization and domestic development goals. While procedural aspects have largely aligned, the substantive differences in patentability criteria, examination standards, and public interest safeguards continue to create friction. Foreign applicants often find the Indian system unpredictable and rigid, while Indian stakeholders are wary of diluting national laws to conform to international pressures (Reddy, 2014). Balancing these competing interests is a recurring theme in India's patent policy discourse.

In addition, the role of the judiciary in interpreting patent laws further shapes the contours of

India’s patent landscape. Landmark judgments such as *Novartis AG v. Union of India* have reaffirmed the importance of Section 3(d) and demonstrated India’s commitment to public health over commercial interests (Novartis AG v. Union of India, 2013). The courts have consistently upheld the government’s right to interpret patentability standards in a manner that promotes innovation without compromising accessibility. These legal interpretations add another layer of complexity to the harmonization process, as they reflect a jurisprudential approach that may not align with the expectations of other PCT countries (Basheer, 2012).

Another important dimension is the growing emphasis on innovation and intellectual property in India’s economic and industrial policy. Initiatives like the National IPR Policy, Make in India, and Startup India reflect the government's intent to strengthen the intellectual property ecosystem (Department for Promotion of Industry and Internal Trade [DPIIT], 2016). These programs aim to foster creativity, support research and development, and promote the commercialization of inventions. However, these goals must be pursued without undermining the delicate balance between exclusive rights and public welfare that lies at the heart of the Indian patent system.

The Indian government also engages in active dialogues with WIPO and other international bodies to represent its unique perspective on intellectual property. Through such interactions, India seeks to contribute to the evolution of global IP norms while safeguarding its national interests (WIPO, 2023). This approach highlights India’s role not just as a participant in the PCT system, but as an influencer of global IP policy, advocating for a more inclusive and development-oriented patent regime.

The Indian patent system and its relationship with the Patent Cooperation Treaty form a multifaceted and evolving landscape. India’s historical commitment to public health and innovation, its adherence to international treaties like TRIPS and the PCT, and its nuanced legal provisions create a unique environment for intellectual property protection. While procedural harmonization with the PCT has brought efficiency and global connectivity, substantive differences continue to reflect India’s autonomous stance on critical issues. Understanding this interplay is essential for policymakers, inventors, legal professionals, and international stakeholders who seek to navigate the challenges and opportunities presented by

India's patent regime in the context of global intellectual property law.[3]

1.1 Importance of Patent Harmonisation in a Globalised Economy

In the era of globalization, intellectual property (IP) has emerged as a pivotal element in shaping innovation-driven economies. Among various forms of IP, patents play a crucial role in promoting technological advancement and economic growth. Patents grant inventors exclusive rights to their inventions, thereby incentivizing creativity, research, and development. However, with increasing cross-border trade, investment, and collaboration in research, disparities in national patent laws have posed significant challenges for businesses and inventors operating in multiple jurisdictions. This has given rise to the concept of patent harmonisation, which refers to the process of aligning patent laws and practices across different countries. The importance of such harmonisation in a globalised economy cannot be overstated, as it fosters legal certainty, reduces duplication of efforts, enhances international cooperation, and promotes equitable access to technology.

In a globalised economy, where companies frequently operate beyond their domestic borders, inconsistent patent laws become a major hindrance. Each country has its own criteria for patentability, application procedures, enforcement mechanisms, and duration of protection. As a result, an inventor or firm seeking international protection must navigate multiple legal systems, increasing the cost and complexity of securing patent rights. Patent harmonisation helps address these inconsistencies by standardising the rules and procedures governing patents. It allows inventors to secure protection for their innovations more efficiently and predictably across borders. When countries adopt similar standards, such as definitions of novelty, inventive step, and industrial applicability, it becomes easier for inventors to comply with the legal requirements of different jurisdictions, saving time and resources.[4]

[3] Basheer, S., & Reddy, P. (2007). The "evolution" of Indian patent law: Stronger protection for pharmaceutical inventions? Journal of Intellectual Property Rights, 12, 123–132.
Chaudhuri, S. (2012). Multinationals and monopolies: Pharmaceutical patents and TRIPS implementation in India. Economic and Political Weekly, 47(40), 48–56.

[4] Correa, C. M. (2002). *Implications of the Doha Declaration on the TRIPS Agreement and Public Health*. World Health Organization.
Department for Promotion of Industry and Internal Trade. (2016). *National IPR Policy*. https://dpiit.gov.in/

One of the key benefits of patent harmonisation is the simplification of the patent application process. Multinational corporations, research institutions, and individual inventors often face significant bureaucratic hurdles when applying for patents in various countries. By harmonising formal and substantive aspects of patent law, such as documentation requirements, language translations, and examination criteria, the international patent filing process becomes less burdensome. Mechanisms like the Patent Cooperation Treaty (PCT) have already made strides in this direction by enabling applicants to file a single international application that is recognised by all member states. Such unified systems reduce redundancy and allow for a centralised search and examination, providing applicants with valuable insights before committing to the national phase of filings. Thus, harmonisation helps streamline global innovation by facilitating easier access to patent protection.

Harmonised patent regimes also enhance legal certainty and predictability, which are essential for fostering investor confidence and economic development. When laws are consistent across countries, businesses can make strategic decisions with greater clarity and reduced legal risk. Investors are more likely to fund research and development projects if they are confident that the resulting inventions will receive robust and enforceable patent protection internationally. Similarly, companies entering new markets can better assess their IP risks and plan accordingly. The predictability offered by harmonised patent systems contributes to a more stable and innovation-friendly business environment, which is critical for the growth of knowledge-based industries in a globalised economy.

Another significant advantage of patent harmonisation is the promotion of international collaboration in science and technology. In today's interconnected world, innovation is increasingly a collaborative process involving multinational teams, research institutions, and industries. However, inconsistent patent laws can hinder joint ventures and collaborative research, especially when parties are uncertain about ownership rights, licensing terms, or infringement liabilities across jurisdictions. Harmonisation can provide a common legal framework that facilitates smooth collaboration, ensures equitable sharing of benefits, and encourages the pooling of intellectual resources. This is particularly important in addressing global challenges such as climate change, health pandemics, and sustainable development, which require coordinated technological solutions across nations.

Patent harmonisation also plays a crucial role in reducing litigation and conflicts over IP

rights. Divergent legal interpretations and enforcement standards often lead to disputes that are costly and time-consuming. When countries align their patent laws, the scope of protection, enforcement mechanisms, and dispute resolution procedures become more predictable and consistent. This not only reduces the frequency of legal conflicts but also makes it easier to resolve disputes when they arise. Harmonised standards also contribute to fair competition by preventing the misuse of patent laws for anti-competitive practices such as forum shopping, patent trolling, or strategic blocking of markets. This creates a more level playing field for both domestic and foreign entities in global markets.

The harmonisation of patent laws is also instrumental in facilitating the transfer and diffusion of technology, especially from developed to developing countries. Patents are often viewed not just as legal tools for exclusivity, but as vehicles for technological dissemination through licensing, partnerships, and foreign direct investment. When patent laws are harmonised, companies in developed countries are more willing to license technologies or enter into joint ventures with firms in developing countries, as they are assured of consistent legal protection. This fosters technology absorption, capacity building, and industrial development in the recipient nations, contributing to inclusive growth. Moreover, harmonisation can support the goals of international development by ensuring that critical technologies in health, agriculture, and environment are accessible to countries that need them most.

In addition to economic and legal benefits, patent harmonisation is vital for ensuring fairness and transparency in the global IP system. The current global patent landscape is often skewed in favour of countries with sophisticated legal systems and strong IP enforcement. Developing and least-developed countries may struggle to keep pace with the complexities of international IP obligations, leading to inequitable outcomes. Harmonisation, if designed inclusively, can help create more balanced standards that reflect the developmental needs of all countries. It can also encourage capacity building and technical assistance, enabling weaker economies to participate meaningfully in the global IP ecosystem. By establishing common minimum standards, harmonisation ensures that all countries adhere to basic principles of IP protection while allowing flexibility to tailor certain provisions based on national interests.

However, while patent harmonisation offers numerous benefits, it must be approached with sensitivity to local contexts and needs. A one-size-fits-all model may not be appropriate for all countries, given the diversity in economic development, innovation capabilities, and public

policy priorities. For instance, countries like India have adopted patent provisions such as Section 3(d) to prevent the evergreening of pharmaceutical patents and ensure access to affordable medicines. Any harmonisation effort must respect such provisions that are rooted in legitimate public interest considerations. Therefore, harmonisation should focus on finding common ground without eroding national policy space. Flexible harmonisation models, such as mutual recognition of examination results, regional patent offices, or minimum harmonisation standards, may provide a balanced approach that accommodates diversity while promoting global convergence.[5]

The role of international organisations in driving patent harmonisation is also significant. Institutions such as the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO), and regional IP bodies play a crucial role in facilitating dialogue, setting guidelines, and providing technical support. Through treaties like the PCT and TRIPS Agreement, these organisations have laid the foundation for harmonised patent regimes. However, continuous efforts are needed to address emerging issues such as digital innovations, artificial intelligence, and biotechnology, which challenge traditional notions of patentability and enforcement. Collaborative forums and stakeholder consultations are essential to ensure that harmonisation evolves in response to technological and societal changes.

In the digital age, patent harmonisation is also important for protecting innovations related to software, data analytics, and AI algorithms. These technologies are inherently global and rapidly evolving, often crossing borders instantaneously. The lack of clarity and consensus on the patentability of such innovations across countries creates legal uncertainty and stifles innovation. Harmonised guidelines on how to treat digital and emerging technologies under patent law would provide greater legal clarity and encourage investment in cutting-edge fields. This is especially relevant as more countries aim to become leaders in digital innovation and seek to attract high-tech investments.

Furthermore, harmonisation helps in building public trust in the patent system. When patent laws are seen as transparent, consistent, and fair across countries, stakeholders are more likely to respect and comply with them. It reduces the perception that patents are tools for

[5] Chaudhuri, S. (2005). The WTO and India's pharmaceuticals industry: Patent protection, TRIPS, and developing countries. Oxford University Press.

monopolisation and rent-seeking by powerful corporations. Instead, harmonised and balanced patent regimes can reinforce the view that patents are legitimate incentives for innovation that benefit society at large. This is crucial for maintaining the social license of IP laws and ensuring that they serve the broader goals of innovation, equity, and public welfare.

Patent harmonisation holds immense importance in a globalised economy. It facilitates the efficient protection of innovations, reduces legal and procedural complexities, fosters international collaboration, and ensures equitable access to technology. Harmonised patent laws create a conducive environment for innovation-led growth by enhancing legal certainty, reducing disputes, and promoting global competitiveness. At the same time, harmonisation must be inclusive, flexible, and responsive to the diverse needs of countries at different stages of development. By balancing global standards with national interests, patent harmonisation can become a powerful tool for advancing technological progress, economic integration, and sustainable development in an increasingly interconnected world.

1.2 The Conflict Between National Patent Law and International Agreements

In the evolving landscape of intellectual property rights (IPR), the intersection between national patent laws and international agreements has become a subject of considerable debate and legal complexity. Patents, by design, are territorial rights granted by individual countries, and each nation historically developed its patent regime in accordance with its unique socio-economic priorities, public policy concerns, and legal traditions. However, as globalisation intensified, the need for a more harmonised and universally coherent system of patent protection gave rise to numerous international agreements, such as the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), the Patent Cooperation Treaty (PCT), and the various regional frameworks managed by entities like the European Patent Office. While these agreements aim to promote a consistent global standard for patent protection, they often come into conflict with the diverse priorities and frameworks of national patent laws. The resulting tension raises profound questions about national sovereignty, access to essential technologies, the balance between innovation and public interest, and the future of global IP governance.

At the heart of this conflict lies the issue of sovereignty. National patent systems are crafted to serve the interests of the country's citizens and economy. These systems often reflect policy decisions on what inventions deserve protection, the conditions for granting patents, and the scope and duration of such protection. In contrast, international agreements seek to harmonise these conditions to facilitate cross-border trade and investment and to ensure a baseline standard of IP protection globally. This harmonisation can sometimes restrict the policy space available to national governments. For instance, countries may be required to grant patents for inventions that, under domestic law, would be excluded due to public interest concerns. This imposition can lead to resentment and resistance, particularly in developing nations that view international agreements as tools of economic dominance by more developed countries.

A classic example of this tension can be seen in the field of pharmaceutical patents. Countries like India have long maintained strict patentability criteria to prevent the practice of "evergreening"—the strategy by which pharmaceutical companies seek to extend patent life by making minor modifications to existing drugs. India's Section 3(d) of the Patents Act is a testament to its commitment to preventing monopolies on life-saving drugs and ensuring access to affordable medicines. However, such provisions often clash with the obligations under international treaties like TRIPS, which require member states to make patents available for any inventions that are new, involve an inventive step, and are capable of industrial application. The ambiguity in interpreting these terms has led to disputes, with multinational corporations challenging domestic laws that they perceive as inconsistent with international standards. These conflicts underscore the difficulty in balancing the global IP framework with local public health and economic development goals.[6]

Another source of conflict arises from the enforcement mechanisms embedded in international agreements. TRIPS, for instance, mandates that member countries provide effective legal remedies for the enforcement of patent rights, including civil and criminal penalties for infringement. While this provision aims to ensure that patents are not merely symbolic, it has led to criticism from several quarters. Developing nations, in particular, argue that such obligations place undue burdens on their legal and administrative systems. Furthermore, stringent enforcement measures can sometimes lead to the prioritisation of IP rights over fundamental rights such as access to information, education, and healthcare. The compulsory

[6] Feroz Ali. (2011). The law of patents with a special focus on pharmaceuticals in India. LexisNexis Butterworths.

licensing provisions under TRIPS, which allow governments to authorise the use of patents without the consent of the patent holder under certain conditions, have been a key area where countries have tried to assert their national prerogatives. However, the use of such flexibilities often invites political and economic pressure from more powerful nations, leading to diplomatic tensions and, in some cases, trade sanctions.

The conflict is not confined to the substance of patent law but extends to procedural aspects as well. International treaties like the PCT aim to streamline the patent application process by allowing inventors to file a single application recognised in multiple jurisdictions. While this system offers clear benefits in terms of efficiency and cost reduction, it can also impose constraints on national patent offices. For instance, the reliance on international search and examination reports may limit the ability of national authorities to make independent decisions based on domestic legal standards. Furthermore, the procedural uniformity sought by international agreements may not adequately accommodate the administrative capacities or policy priorities of all countries, particularly those with limited resources.

Regional patent frameworks add another layer of complexity to the conflict between national and international regimes. Entities like the European Patent Office and the African Regional Intellectual Property Organization provide mechanisms for obtaining patent protection across multiple countries through a single application. While these systems promote regional integration and reduce duplication of effort, they can also dilute the authority of individual national patent offices. Additionally, the coexistence of regional, national, and international mechanisms creates a multilayered legal environment that can be confusing and costly for inventors, especially small and medium-sized enterprises.

Cultural and historical differences also play a role in shaping the conflict between national and international patent laws. Many developed countries, which are net exporters of technology, tend to favour strong and expansive patent rights. In contrast, developing nations, which are often net importers of technology, seek a more balanced approach that prioritises public interest and access to knowledge. This divergence in priorities is often reflected in the negotiating positions adopted by countries in international forums. For example, during the negotiation of TRIPS, developing countries pushed for provisions that would allow them to use IP flexibilities to meet development goals. Although some such provisions were included, the dominant thrust of TRIPS remains tilted in favour of strong IP protection, leading to

persistent dissatisfaction and calls for reform.

The growing significance of digital technologies has further complicated the relationship between national and international patent laws. Issues such as software patentability, protection of algorithms, and data-related innovations are treated differently across jurisdictions. While some countries, like the United States, allow the patenting of software-related inventions under specific conditions, others, such as many European nations, impose stricter limitations. This inconsistency leads to strategic behaviour by applicants and creates uncertainties in the global marketplace. Efforts to harmonise standards in emerging areas have thus far been limited, and this regulatory gap highlights the challenges of creating a universally accepted patent framework in a rapidly changing technological environment.

The investor-state dispute settlement (ISDS) mechanisms included in some international investment agreements further illustrate the conflict between national laws and international obligations. Under ISDS provisions, foreign investors can sue host governments for measures that allegedly violate their IP-related investment rights. This has led to cases where pharmaceutical companies have challenged national decisions to reject patents or issue compulsory licenses. Critics argue that such mechanisms undermine the sovereignty of national courts and democratic decision-making processes, allowing corporations to bypass domestic legal systems in favour of international arbitration panels. These disputes reveal the potential of international agreements to constrain national policy space and have fuelled a broader debate about the legitimacy and accountability of the global IP system.

Amidst these tensions, the role of international institutions like the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO) becomes critical. These organisations serve as platforms for negotiation, dispute resolution, and capacity building. However, they are also often criticised for reflecting the interests of more powerful countries and for lacking effective mechanisms to ensure equitable participation by developing nations. Efforts to reform the global IP system must therefore include measures to democratise these institutions, enhance transparency, and build consensus on contentious issues.

National governments, for their part, have sought various strategies to navigate the conflict between domestic patent laws and international agreements. Some have adopted legislation that incorporates TRIPS flexibilities more explicitly, such as allowing parallel imports or

setting high thresholds for patentability. Others have forged regional alliances to collectively advocate for more balanced international rules. Civil society organisations, academic institutions, and public interest groups have also played a crucial role in highlighting the implications of global IP rules and pushing for more inclusive policymaking processes.

The conflict between national and international patent regimes is further intensified by geopolitical dynamics. Trade negotiations increasingly include IP provisions that go beyond existing international obligations—a phenomenon known as "TRIPS-plus" standards. These provisions often demand stricter enforcement, longer patent terms, or limitations on the use of compulsory licenses. Countries entering into such agreements may find themselves locked into commitments that exceed their domestic legal standards and limit their ability to adapt IP policies in response to changing national needs. The proliferation of bilateral and regional trade agreements with IP chapters thus raises concerns about the erosion of national autonomy and the entrenchment of global IP norms that favour corporate interests.

Ultimately, the challenge lies in finding a sustainable and equitable balance between national sovereignty and international cooperation. A global IP system that respects the diversity of national contexts while providing a coherent framework for cross-border innovation is essential. This requires a paradigm shift from a purely rights-based approach to one that emphasises responsibilities, public interest, and development goals. Greater emphasis must be placed on building consensus through inclusive dialogue, recognising the legitimate concerns of all stakeholders, and promoting capacity building in countries that lack the resources to fully engage with the complexities of international patent law.

The conflict between national patent laws and international agreements is emblematic of broader tensions in the global governance of knowledge and innovation. While international treaties aim to create uniformity and predictability, they can sometimes constrain national policy autonomy and lead to inequitable outcomes. Reconciling these tensions requires a nuanced approach that acknowledges the importance of both global standards and local priorities. By fostering dialogue, enhancing flexibility, and promoting fairness, it is possible to develop a patent system that supports innovation while also advancing public interest and sustainable development.

1.3 Statement of the Problem:

India faces the complex challenge of aligning its patent law with the TRIPS Agreement while ensuring access to affordable medicines and protecting public health, amidst increasing global pressures to adopt TRIPS-plus standards.

1.4 Significance of the Research

This research holds critical significance in the current global intellectual property landscape, especially for developing countries like India that must navigate the dual pressures of complying with international agreements such as TRIPS and addressing domestic socio-economic priorities, particularly public health. The study explores how India has incorporated TRIPS-compliant provisions into its patent law while simultaneously introducing mechanisms—such as Section 3(d) and compulsory licensing—to safeguard access to affordable medicines and promote technological self-reliance.

By conducting a comparative analysis with Brazil and South Africa, two other major developing economies facing similar challenges, this research provides broader insights into how TRIPS flexibilities can be strategically used to protect public interest. The Brazilian model, with ANVISA's regulatory oversight, and South Africa's ongoing patent reform efforts offer useful policy lessons and legislative innovations that India can adapt and implement. The study also critiques TRIPS-plus pressures arising from bilateral and multilateral trade negotiations, which often seek to impose stricter IP standards beyond TRIPS, threatening the delicate balance between patent protection and public welfare.

This research contributes to legal scholarship by evaluating not only the legislative and judicial trajectory of India's patent law post-TRIPS, but also the implications of global IP diplomacy. It provides a nuanced understanding for policymakers, legal practitioners, public health experts, and academics interested in intellectual property rights, international trade, and access to medicines. Ultimately, the study supports the development of a balanced patent system that fosters innovation while ensuring that essential technologies remain accessible to the people who need them most.

1.5 Scope Of Research

This research focuses on exploring the intersection between the Indian Patent Act and international agreements, particularly the Patent Cooperation Treaty (PCT). It covers the

legal, economic, and policy dimensions of patent harmonisation in the context of a globalised economy. The study analyses the challenges India faces in aligning its domestic patent laws with international obligations while safeguarding national interests such as public health and access to technology. It also examines the broader implications of such harmonisation for developing countries. The scope is limited to legal frameworks, policy analysis, and international patent cooperation, without delving into technical patent drafting or specific industry-based patents.

1.6 Research objective

1. To examine the existing framework of the Indian Patent Act and its compatibility with international treaties, especially the Patent Cooperation Treaty (PCT).
2. To identify and analyse the major challenges faced in harmonizing India's national patent laws with global patent standards.
3. To explore the legal, economic, and technological implications of patent harmonisation in a globalised economy for India.
4. To understand the conflict areas between national patent sovereignty and international obligations under agreements like TRIPS and PCT.
5. To compare the impact of global patent harmonisation on innovation, access to technology, and public welfare in developing countries like India, South Africa and China.

1.7 Research Question

How has India harmonized its patent law with the TRIPS Agreement while safeguarding public health interests, and what policy lessons can be drawn from comparative global frameworks for future IP negotiations?

1.8 Research Methodology

The research methodology offers a systematic and empirical framework for investigating the challenges in harmonising the Indian Patent Act with the Patent Cooperation Treaty (PCT). This study adopts an empirical legal research approach to examine existing patent laws, judicial precedents, statutory provisions, and case studies in the context of the PCT. The methodology aims to provide both theoretical and practical insights into the legal challenges faced by the patent system in India with respect to harmonisation with the PCT.

This study utilises an empirical and analytical research design to assess the legal and institutional mechanisms governing patent law in India and its application to the PCT. The empirical research focuses on analysing real-life judicial decisions, statutory frameworks, and relevant case law, rather than theoretical assumptions. It explores the existing patent laws and their implications for inventors and innovators, including the protection of intellectual property such as inventions, designs, and utility models. The analytical aspect of the research involves a critical evaluation of legal principles, judicial interpretations, and the gaps in existing patent law with respect to the PCT. The study examines cases where patent infringements occurred in India and assesses how the courts have interpreted patent provisions under the Indian Patent Act. It also focuses on analysing the challenges posed by international patent filing, cross-border patent protection, and the rise of global innovation, which have not been fully addressed by existing patent law.

This study is based on secondary data sources, including judicial precedents, legislative enactments, government publications, and scholarly articles. The key sources of data include:

Landmark judgments from the Supreme Court of India and various High Courts interpreting patent law in the context of international treaties, particularly the PCT.

Comparative analysis of case laws from international jurisdictions (e.g., the United States, European Union) to understand how they have handled patent issues in relation to the PCT.

Analysis of cases involving inventors, patent holders, and patent examiners, illustrating challenges and ambiguities in the protection of intellectual property in patents.

The Indian Patent Act, 1970, which governs patent protection in India, including provisions for international patent filing and enforcement. The Patent Cooperation Treaty, 1970, and its relation to patent protection in India, especially concerning international patent applications and cross-border protection. International treaties, such as the Paris Convention for the Protection of Industrial Property, which India is a part of, influencing patent law in India.

Reports from the Law Commission of India on the need for reforms in patent law to accommodate international treaties like the PCT. Studies from the Ministry of Commerce and Industry on the state of patent protection and enforcement mechanisms in India.

Parliamentary debates and reports discussing the impact of patent infringement and the need for harmonisation with the PCT. Analysis of legal textbooks, commentaries, and journal articles discussing the intersection of patent law and the PCT. Review of research studies examining the impact of patent protection on innovation, international patent filing, and the economic implications of intellectual property rights in patents. By combining these diverse

sources, the study ensures a comprehensive understanding of the challenges and opportunities related to harmonising the Indian Patent Act with the PCT.

CHAPTER 2 : TRIPS AND INDIAN PATENT LAW

2.1 Introduction

The global intellectual property (IP) landscape witnessed a significant transformation with the coming into force of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) in 1995. Enforced under the aegis of the World Trade Organization (WTO), TRIPS introduced, for the first time, a uniform and enforceable set of IP standards applicable across all member nations. This agreement was intended to promote innovation, stimulate technology transfer, and provide a predictable framework for international trade involving IP-protected goods. However, its implications were not uniform across countries. For developing economies like India, TRIPS compliance poses a complex balancing act between integrating global standards and addressing socio-economic realities—particularly public health concerns and access to affordable medicines.

Prior to TRIPS, India's patent system was designed with strong public interest safeguards. The Indian Patents Act of 1970, influenced by the recommendations of the Ayyangar Committee, excluded product patents in food, chemicals, and pharmaceuticals to foster domestic innovation and ensure access to essential goods. This approach catalyzed the rise of a robust generic pharmaceutical industry in India, earning the country a reputation as the "pharmacy of the developing world." However, the obligations imposed by TRIPS required India to make sweeping changes to its patent regime, including the introduction of product patents across all technological fields and uniform patent protection for a minimum of 20 years.

Despite its resistance to some of TRIPS' more stringent features, India recognized the inevitability of compliance. But it did not rush to adopt the reforms in haste. Instead, India employed the maximum transition period available under TRIPS for developing countries—extending up to 2005—to incrementally bring its laws in line with the agreement. This staggered approach allowed India to introduce necessary legal, procedural, and institutional reforms while simultaneously developing robust mechanisms to mitigate any adverse socio-

economic consequences.

The process of harmonizing Indian patent law with TRIPS unfolded through a series of legislative amendments in 1999, 2002, and 2005. Each phase reflected a strategic alignment with international requirements, accompanied by domestic policy safeguards to prevent misuse of the patent system. During this period, India introduced vital mechanisms such as Section 3(d) to prevent the evergreening of pharmaceutical patents, and robust compulsory licensing provisions under Section 84 to ensure continued access to affordable medicines. In addition, India established pre-grant and post-grant opposition mechanisms, which enhanced transparency and public participation in the patent granting process—tools that many developed nations did not provide.

Importantly, India's approach to TRIPS compliance has been widely recognized as a model for other developing nations. Rather than passively accepting the agreement's terms, India proactively engaged with the flexibilities built into the TRIPS framework—particularly those emphasized in the Doha Declaration on TRIPS and Public Health (2001)[7]. India's experience has thus become emblematic of how countries can meet international legal obligations while tailoring implementation in line with national interests and developmental priorities.
This chapter seeks to unpack the various dimensions of this harmonization process. It begins with a chronological examination of the legislative amendments India undertook to achieve TRIPS compliance. It then explores the incorporation of specific TRIPS provisions into domestic law and the creation of institutional and procedural frameworks, including opposition systems and compulsory licensing. Further, it evaluates the evolution of India's patent law post-TRIPS, focusing on the key features that distinguish India's approach from other WTO members. Ultimately, the chapter reflects on the challenges, successes, and lessons from India's journey in balancing innovation, trade obligations, and public welfare in the domain of patent law.

2.2 Incorporation of TRIPS into the Indian Patent Framework

India's incorporation of the TRIPS Agreement into its patent law regime marks a significant turning point in the evolution of its intellectual property system. When India became a

[7] Basheer, Shamnad, "India's Patent Policy: An Overview of Pharmaceutical Patentability and Access to Medicines", (2012) 8(1) *Indian Journal of Law and Technology* 15

founding member of the World Trade Organization (WTO) in 1995, it simultaneously agreed to implement the obligations outlined in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). However, recognizing the economic and developmental disparities between developed and developing nations, the TRIPS Agreement allowed for phased compliance, granting India a transitional period of up to ten years (until January 1, 2005) to amend its national laws to align with the minimum standards mandated under TRIPS.

During this transitional period, India undertook a cautious and measured approach, carefully evaluating each amendment to balance its international commitments with national priorities, particularly the need to ensure access to affordable medicines and protect public health. The country's strategy was not merely about fulfilling obligations, but about preserving the autonomy to frame laws that met the socio-economic realities of a developing country. India utilized the flexibilities offered under TRIPS, such as allowing for parallel imports and compulsory licensing, and incorporated safeguard mechanisms to prevent misuse of patent rights, particularly in the pharmaceutical sector.

One of the earliest changes was the introduction of the "mailbox" provision under the Patents (Amendment) Act, 1999. This was in response to Article 70.8 and 70.9 of TRIPS, which required WTO member countries that did not provide product patents in certain areas—particularly pharmaceuticals and agricultural chemicals—to establish a mechanism for receiving and preserving such applications until product patent protection was made available. Alongside this, India introduced Exclusive Marketing Rights (EMRs) as an interim provision to allow some degree of protection for those filing patent applications in the mailbox system[8].

The Patents (Amendment) Act, 2002 was the next major legislative step, redefining key terms like "invention" and "inventive step" to align with TRIPS language. This Act strengthened the legal framework for patentability and included provisions related to patentability criteria, term of protection (now 20 years), and expanded rights of patentees. However, India also took care to retain important exclusions from patentability to prevent the monopolization of basic scientific principles, traditional knowledge, and essential drugs without real innovation.

The final step in India's TRIPS compliance came with the Patents (Amendment) Act, 2005, which formally introduced product patent protection for pharmaceuticals and agrochemicals.

[8] Watal, Jayashree, *Intellectual Property Rights in the WTO and Developing Countries* (Oxford University Press, 2001

While this was a substantial shift from India's earlier process patent regime, the law was framed in a manner that preserved public interest safeguards. Notably, the inclusion of Section 3(d) served as a protective clause against the patenting of trivial modifications of known drugs—a direct response to concerns about "evergreening" by pharmaceutical giants.

Through these amendments, India successfully harmonized its domestic patent law with TRIPS requirements while preserving the flexibility to address its developmental and public health needs. The process demonstrated India's ability to navigate the international IP landscape strategically, adopting a patent regime that conforms to global standards but also integrates mechanisms to ensure equitable access to essential goods. This careful legislative engineering has since served as a model for other developing countries seeking to strike a similar balance in their IP frameworks.

2.3. Post-TRIPS Progression of India's Patent Law: Patents (Amendment) Acts of 1999, 2002, and 2005

The journey of harmonizing India's patent law with the TRIPS Agreement was neither instantaneous nor uniform—it evolved through a series of three key legislative amendments over the course of a decade. These amendments represent India's strategic and phased compliance with TRIPS, ensuring that international obligations were met without compromising public health safeguards, innovation policy, or national economic interests. Each amendment reflected a careful balancing act between facilitating innovation and preserving access to medicines, which remains a cornerstone of India's developmental ethos.

2.3.1 Patents (Amendment) Act, 1999: Introduction of the Mailbox and EMRs

The first legislative milestone came with the Patents (Amendment) Act, 1999, passed to comply with TRIPS Article 70.8 and 70.9. As India did not allow product patents for pharmaceuticals and agro-chemicals at the time, it was required to implement a "mailbox" mechanism for accepting patent applications in these fields from January 1, 1995. These applications were to be examined only after the full transition to product patent protection in 2005.

Additionally, the Act introduced Exclusive Marketing Rights (EMRs), which allowed companies that had filed in the mailbox system to obtain temporary marketing rights for up to five years, or until a product patent was granted or rejected. This was intended to bridge the gap during the transition period, giving inventors some market exclusivity. While EMRs

provided limited protection, they were controversial due to high prices of some medicines under EMRs (e.g., Novartis' Glivec), which underscored the future need for robust public interest safeguards.

2.3.2 Patents (Amendment) Act, 2002: Redefining Patentability Criteria

The second major amendment, the Patents (Amendment) Act, 2002, was a comprehensive effort to overhaul India's patent law and bring it further in line with TRIPS obligations. Key features of this amendment included:

- Extension of Patent Term: The term of patents was uniformly extended to 20 years from the date of filing, as required by TRIPS Article 33.

- Redefinition of Key Concepts: The definitions of "invention", "inventive step", and "capable of industrial application" were redefined to meet international standards. The new definition of inventive step emphasized a "technical advance" and an "economic significance" to ensure that only meaningful innovations were granted patent protection.

- Establishment of the Appellate Board: The Intellectual Property Appellate Board (IPAB) was established for hearing appeals related to patent decisions, replacing the High Court's jurisdiction in most cases and speeding up resolution of disputes.

- Publication of Patent Applications: A new provision mandated the publication of patent applications 18 months after filing, promoting transparency and enabling third-party monitoring.

This amendment paved the way for a more standardized and efficient patent system while preserving exclusions under Section 3, which prohibits patents on mere discoveries, natural substances, traditional knowledge, or mathematical and business methods.

2.3.3 Patents (Amendment) Act, 2005: Introduction of Product Patents and Public Health Safeguards

The Patents (Amendment) Act, 2005, the final and most significant reform in India's TRIPS compliance process, came into effect on January 1, 2005. This amendment brought India fully into compliance with TRIPS by introducing product patent protection in all fields of

technology, including pharmaceuticals and agro-chemicals.

However, what set India apart was its intelligent and deliberate incorporation of public health safeguards to balance the newfound rights of patent holders with the pressing needs of its population.

Key features included:

- **Section 3(d): Preventing Evergreening**
  One of the most discussed and debated provisions globally, Section 3(d) was introduced to prevent patenting of minor modifications of existing drugs (like new forms, dosages, or derivatives) unless they resulted in a significant improvement in therapeutic efficacy. This provision was upheld by the Supreme Court in Novartis AG v. Union of India (2013) and remains a critical tool in preventing evergreening of patents.
- **Compulsory Licensing Provisions (Section 84):**
  While compulsory licensing existed earlier, the 2005 amendment clarified the procedure and grounds. A license can be granted after three years from the date of grant if:
    - The patented invention is not available to the public at a reasonably affordable price.
    - The reasonable requirements of the public are not being met.
    - The invention is not being worked on in the territory of India.
- The landmark Natco Pharma v. Bayer (2012) case demonstrated India's readiness to use these provisions in favor of public health.
- Pre-grant and Post-grant Opposition Mechanisms:
  The amendment introduced a dual opposition system:
    - Pre-grant opposition allows any person to challenge a patent application before it is granted.
    - Post-grant opposition may be filed within one year of the grant of the patent by any "interested person."
- These provisions ensure that invalid patents do not get through the system unchecked and empower stakeholders to participate in the examination process.
- Working of Patents and Compulsory Licensing:
  Patentees must file Form 27 annually, declaring whether the patent is being "worked" (i.e., used or manufactured) in India. Failure to work a patent adequately can form the basis for a compulsory license, a provision that reinforces India's emphasis on utility

and access over mere ownership.

2.4 Mechanisms Introduced to Safeguard National Interests: Pre-Grant and Post-Grant Opposition, and Compulsory Licensing

Following the adoption of TRIPS and the substantial amendments to the Patents Act in 1999, 2002, and 2005, India incorporated several mechanisms designed to protect public interest and ensure that the expanded scope of patent rights would not compromise its developmental and public health objectives. These mechanisms—particularly the pre-grant and post-grant opposition systems and the provision for compulsory licensing—stand as important pillars in India's strategy to maintain the balance between encouraging innovation and securing access to essential goods, especially medicines.

2.4.1 Pre-Grant and Post-Grant Opposition Mechanisms

To ensure that patent protection is only granted for genuine and novel inventions, India strengthened its opposition framework by introducing two levels of challenge: pre-grant opposition and post-grant opposition. These procedures give third parties and stakeholders the opportunity to prevent or revoke patents that are wrongly granted or do not meet statutory requirements.

4.1.1 Pre-Grant Opposition

Pre-grant opposition is provided under Section 25(1) of the Patents Act and allows *any person* to oppose a patent application after its publication but before it is granted. This wide locus standi is significant, as it enables not just competitors but also civil society organizations and public health activists to challenge undeserving applications.

Grounds for pre-grant opposition include:

- Lack of novelty
- Obviousness or lack of inventive step
- Non-patentable subject matter under Sections 3 and 4
- Insufficient disclosure
- Wrongful obtaining of the invention
- Failure to disclose information related to foreign filings

Pre-grant opposition proceedings are decided by the Controller of Patents. While there have been concerns that pre-grant oppositions could cause delays, they serve as a crucial check

against the granting of frivolous or abusive patents—especially in the pharmaceutical sector. Notably, the pre-grant opposition mechanism was used effectively in the Novartis case to initially block the patenting of an incremental form of the cancer drug imatinib mesylate.

4.1.2 Post-Grant Opposition

Under Section 25(2) of the Patents Act, an "interested person" may file a post-grant opposition within 12 months of the patent being granted. Unlike pre-grant opposition, this is a more structured proceeding, adjudicated by an Opposition Board constituted by the Controller. The Board gives its recommendations after hearing both the patentee and the opponent.

Grounds for post-grant opposition largely mirror those of the pre-grant system but involve a more thorough examination. This mechanism helps correct errors that may have occurred during the examination process and reinforces accountability in the grant of patents.[9]

Together, these opposition mechanisms reflect India's effort to ensure a transparent, participatory, and vigilant patent system. They have been especially useful in preventing evergreening and upholding Section 3(d), thereby protecting affordable access to life-saving medicines.

2.4.2 Compulsory Licensing: Balancing Rights and Access

The provision for compulsory licensing (CL) under Sections 84–92 of the Patents Act is one of the most prominent tools India has used to ensure access to essential medicines while staying within the boundaries of TRIPS. Compulsory licensing enables a third party to manufacture and sell a patented product without the consent of the patent holder under certain conditions.

Grounds for Compulsory Licensing

Under Section 84(1), any person may apply for a compulsory license after three years from the date of grant of a patent if any of the following conditions are met:

- The reasonable requirements of the public are not being satisfied.
- The patented invention is not available to the public at a reasonably affordable price.
- The patented invention is not being "worked" in India (i.e., not being manufactured adequately supplied in the country).

The applicant must demonstrate that efforts were made to obtain a voluntary license from the

[9] Ghosh, Shubha, "Legal History of Patent Law in India", (2014) 9(3) *Journal of Intellectual Property Law & Practice* 213.

patentee but were unsuccessful. However, in cases of national emergency or extreme urgency, under Section 92, the government can issue a compulsory license without prior negotiation.

2.4.3 Compulsory Licensing Beyond Pharmaceuticals

Although CLs have been primarily used in the pharmaceutical sector, Indian law permits their application across other fields like agriculture, biotechnology, and green technology. Given the rising challenges of climate change and technological disparity, CL provisions could play a vital role in facilitating access to clean energy innovations, seeds, and environmentally sustainable technologies.

2.4.4 International Implications and Resistance

India's CL regime has attracted scrutiny and opposition from developed countries and multinational corporations. The United States Trade Representative (USTR) has repeatedly criticized India's IP regime in its Special 301 Report, often citing CLs as a trade barrier. However, India's position is consistent with TRIPS Article 31, which explicitly allows for compulsory licensing under clearly defined conditions.

2.5 Judicial Interpretation and Global Pressure: Defending TRIPS Compliance Through Indian Courts and Diplomacy

As India transitioned its patent law to align with TRIPS obligations, it found itself at the center of both domestic scrutiny and international pressure. While the legislative framework was carefully amended to incorporate TRIPS-compliant provisions, the real test lay in their interpretation and enforcement. Indian courts played a crucial role in defending the public interest by ensuring that the laws were implemented in a manner consistent with the goals of accessibility and innovation equity. At the same time, India faced substantial resistance from developed countries and multinational pharmaceutical lobbies attempting to dilute the flexibilities allowed under TRIPS.

India's legal structure, particularly with regard to Section 3(d) of the Patents Act and its compulsory licensing framework, has been consistently validated through judicial interpretation. Courts have emphasized that TRIPS compliance does not require the blind granting of patents but allows nations the autonomy to introduce checks to prevent abuse. Indian judiciary, through critical rulings, has ensured that the balance between patent protection and public health is preserved. For instance, in matters involving high-cost patented drugs, courts have often denied injunctions or upheld compulsory licenses to protect patient access.

While this internal legal maturity was developing, India was also the target of repeated external pressure. Developed nations, particularly the United States and members of the European Union, pushed for TRIPS-plus obligations through bilateral and multilateral trade agreements. These included demands for data exclusivity, longer patent terms, and stringent enforcement measures—provisions that go beyond TRIPS and severely limit developing countries' policy space.

In response, India has consistently adopted a defensive and strategic stance. It has resisted such provisions during trade negotiations, particularly in the India-EU Free Trade Agreement and the RCEP talks. Moreover, India has regularly found itself on the United States Trade Representative's (USTR) Special 301 Priority Watch List, with allegations that its patent environment does not favor innovators. However, India has pushed back by highlighting that its legal system operates fully within the flexibilities permitted under TRIPS, particularly under Articles 7, 8, and 31, and in accordance with the Doha Declaration on TRIPS and Public Health.

Furthermore, India has taken a proactive role in international IP policy debates. It has joined hands with countries like Brazil and South Africa to form a coalition of nations advocating for equitable access to medicines and fairer patent norms. India has also used platforms such as WIPO, WTO, and the United Nations to stress the importance of development-oriented IP regimes and to resist the standardization of TRIPS-plus conditions across the Global South.

A clear example of India's global leadership was seen during the COVID-19 pandemic when it, along with South Africa, proposed a temporary waiver of certain TRIPS provisions to ensure global access to vaccines and treatments. The proposal sparked a global conversation on the need to reform international IP regimes to prioritize human lives over monopolistic profits.

In conclusion, India's post-TRIPS patent landscape demonstrates a judicious balance of legal rigor and diplomatic assertiveness. By embedding public interest within its patent regime and defending it both in courts and on international platforms, India has created a model for developing countries to navigate global IP compliance without sacrificing developmental and humanitarian objectives.

2.5.1 Global Pressure and India's Diplomatic Response

Despite India's lawful use of TRIPS flexibilities, it has faced sustained pressure from developed nations, especially through bilateral trade negotiations and international lobbying.

TRIPS-Plus Pressures

Countries like the United States and trade blocs like the European Union have repeatedly attempted to push India into adopting TRIPS-plus obligations—standards that go beyond what TRIPS requires. These often include:

- Data exclusivity provisions, which would restrict generic manufacturers from using clinical trial data.
- Patent term extensions, to compensate for delays in patent approval.
- Stronger enforcement measures, including border seizures of generics in transit.

Such provisions can severely restrict access to generics and undermine public health goals. India has resisted these clauses in its negotiations, particularly in agreements like the India-EU FTA and the now-stalled Regional Comprehensive Economic Partnership (RCEP).

India has also continued to advocate for a development-oriented IP system through active participation in the WTO, WIPO, and UN forums. It has aligned itself with other developing nations, including Brazil and South Africa, forming a united front that challenges excessive IP monopolies and promotes technology transfer and innovation capacity in the Global South.

2.5.2 India's Role as a Global IP Thought Leader

Rather than being a passive rule-follower, India has increasingly positioned itself as a thought leader in global IP policy, promoting a humanitarian and access-based approach to intellectual property.

- India has contributed to the WIPO Development Agenda, which emphasizes the need to tailor IP regimes to development priorities.
- It played a critical role in the Doha Declaration negotiations and continues to advocate for more equitable interpretations of TRIPS.
- India's experience is frequently cited by other developing countries seeking to design patent laws that are TRIPS-compliant but not TRIPS-plus.

India's approach has also influenced global debates around vaccine equity and pandemic response, with its joint proposal with South Africa at the WTO to temporarily waive certain TRIPS provisions during the COVID-19 crisis receiving widespread support.

CHAPTER 3: CHALLENGES IN HARMONISING THE IPA ACT WITH PCT

Harmonizing the Indian Patent Act with the Patent Cooperation Treaty (PCT) presents multiple challenges that stem from the differences in legal, economic, and social priorities between India and the international standards set by the PCT. The PCT, as an international treaty administered by the World Intellectual Property Organization (WIPO), aims to simplify the process of patent protection by enabling applicants to file a single international patent application that can be recognized by over 150 contracting states. India, as a signatory to both the PCT and the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, faces significant challenges in aligning its domestic patent law with these global frameworks. These challenges are not merely legal in nature but are also deeply rooted in India's developmental needs, public policy considerations, and the protection of public health.[10]

One of the primary challenges in harmonizing India's patent laws with the PCT is the divergence in the scope of patentability. The Indian Patent Act, particularly with the amendments made in 2005 to comply with the TRIPS Agreement, incorporates stricter patentability criteria, especially with respect to pharmaceutical patents. Section 3(d) of the Indian Patent Act, which was designed to prevent "evergreening" (a practice where patents are extended through minor modifications of existing inventions), significantly restricts the scope of patentability for pharmaceutical products. This provision has been a source of tension between India and multinational pharmaceutical companies that seek broader patent protection. Under the PCT system, however, the patentability of pharmaceutical inventions is far more lenient, which creates a conflict with India's stricter national provisions. Indian policymakers are wary of the potential adverse impacts of granting patents on minor modifications of existing drugs, which could restrict access to affordable medicines, especially in a country where a significant portion of the population depends on low-cost generic drugs.

[10] Rai, P. (2009). *India and the Patent Cooperation Treaty: Building capacity while staying unique*. Journal of Intellectual Property Rights, 14(4), 321–328.

Another significant challenge is the issue of compulsory licensing, which is a critical feature of the Indian Patent Act. The Act allows for compulsory licensing of patents, particularly when the patented product is not available at a reasonable price or when the patented invention is not being worked on in the country. This provision is essential for safeguarding public health, particularly in the pharmaceutical sector, by ensuring access to life-saving drugs. However, the PCT system does not explicitly provide for compulsory licensing, and this divergence presents a legal and practical challenge for India. India's commitment to the TRIPS Agreement allows it to issue compulsory licenses under certain conditions, but harmonizing this provision with the PCT's more restrictive stance on compulsory licensing creates a potential conflict. This situation underscores the tension between international patent obligations, which often prioritize the rights of patent holders, and national patent policies that prioritize public health and access to essential goods.

The protection of traditional knowledge is another area where the harmonization of India's patent system with the PCT faces significant challenges. India has long been a steward of rich biodiversity and traditional knowledge, particularly in areas such as Ayurveda, traditional medicine, and organic farming. India's patent system incorporates provisions that aim to protect traditional knowledge from being patented without due recognition and benefit-sharing with the local communities. This issue gained international attention during the controversy surrounding the patenting of turmeric by Western entities in the 1990s, which led to greater focus on safeguarding traditional knowledge in the patenting system. The PCT, however, does not have specific provisions to protect traditional knowledge, and many countries, including India, have expressed concerns about the misappropriation of indigenous knowledge through international patent filings. The lack of a global framework to protect traditional knowledge in the PCT system poses a significant challenge for India, as it seeks to ensure that its indigenous practices are not exploited through the global patent system.

India's approach to patent law also includes significant exceptions aimed at balancing innovation with access to knowledge and resources. For example, the Indian Patent Act contains provisions that exclude patents for inventions related to certain areas such as food, drugs, and microorganisms. These exclusions are critical to ensuring that basic human needs are not monopolized by patent holders. In contrast, the PCT system, which focuses on standardizing patent protection across member states, does not accommodate such broad exclusions, resulting in potential conflicts when a patent is filed internationally under the PCT

and then denied by India due to these exclusions. The absence of a clear and universally accepted framework for such exclusions in the PCT makes it difficult for India to ensure that its public policy objectives—such as safeguarding food security and access to essential medicines—are not undermined by patent filings made under the PCT.

The differing legal philosophies between India and the PCT system also complicate the harmonization process. India's patent law is deeply rooted in the concept of socio-economic development, and its approach to patenting reflects a broader commitment to addressing public needs, especially in sectors like healthcare, education, and agriculture. The PCT, on the other hand, operates on the premise that patents are primarily a tool for promoting innovation and technological advancement, often with a strong emphasis on rewarding private investment in research and development. While the PCT framework seeks to create a uniform patent protection system, India's approach takes into account the need for flexible patent laws that can respond to the country's specific developmental challenges. This difference in underlying legal philosophies makes it difficult to create a seamless integration between Indian patent law and the PCT system.

The issue of patent term extensions also poses challenges in the context of harmonizing India's patent system with the PCT. Under the PCT, patent holders have the ability to extend the term of their patents in certain cases, particularly in the pharmaceutical industry, to account for delays in regulatory approval. This provision is often seen as a way to compensate patent holders for the time it takes to bring a product to market. In India, however, the concept of patent term extension is controversial. Critics argue that extending patent terms unfairly prolongs monopoly rights, particularly in sectors like pharmaceuticals, where patent extensions can prevent the entry of generic competitors into the market. The Indian Patent Act has therefore been reluctant to adopt patent term extensions, particularly in light of the public health concerns associated with prolonged exclusivity. Harmonizing this aspect of patent law with the PCT would require India to reconsider its stance on patent term extensions, which could be seen as compromising public access to affordable medicines.

The procedural and administrative challenges of harmonizing India's patent system with the PCT also cannot be ignored. The Indian patent office, while making significant strides in improving efficiency, still faces challenges related to delays in patent examination, insufficient human resources, and outdated infrastructure. The PCT process requires a high

level of coordination between national patent offices and international patent bodies, and the Indian Patent Office must ensure that its systems are capable of processing international patent applications in a timely and efficient manner. Additionally, India must navigate the complexities of dual patenting—where an applicant files both a national application under the Indian Patent Act and an international application under the PCT. This administrative burden can place significant strain on the country's already overburdened patent office and may lead to delays or inconsistencies in the patenting process.

Finally, the ongoing shift towards stronger patent protection in global trade agreements, such as the Regional Comprehensive Economic Partnership (RCEP) and bilateral free trade agreements, adds another layer of complexity to the harmonization process. These agreements often push for stronger patent protection than what is required under the PCT and can create tensions with India's more balanced approach to patent law. The negotiation of such trade agreements requires India to carefully navigate the potential for increased patent protection that could undermine its policy goals in public health, access to knowledge, and innovation.

3.1 Procedural Challenges in Harmonizing the Indian Patent Act with the Patent Cooperation Treaty (PCT)

Harmonizing the procedural aspects of the Indian Patent Act with the Patent Cooperation Treaty (PCT) involves a number of administrative and bureaucratic challenges that must be carefully addressed. Procedural mechanisms are the foundation of an efficient patent system. They determine how applications are filed, examined, granted, and enforced. In India's case, while there has been considerable progress in aligning some of its patent procedures with international norms, several procedural inconsistencies and inefficiencies continue to impede seamless harmonization with the PCT framework.

One of the primary procedural challenges lies in the complexity of the patent filing and examination process in India. While the PCT offers a streamlined application system where inventors can file a single international application that can later be validated in multiple jurisdictions, the Indian patent system maintains its own distinct set of procedural requirements. For instance, applicants must file a national phase application in India within 31 months from the priority date of the PCT application, along with translations and various

forms. The administrative burden of preparing, translating, and submitting these documents under tight deadlines often causes procedural bottlenecks for inventors, especially those from non-English speaking countries or from smaller firms with limited resources.

The delays in patent examination and grant processes in India also present a significant procedural hurdle. Despite reforms and digitization efforts, the Indian Patent Office (IPO) continues to struggle with a backlog of applications, primarily due to a shortage of patent examiners and technical staff. This delay contrasts sharply with the expectations of efficiency and timeliness promoted by the PCT. When international applicants enter the Indian national phase, they often encounter prolonged waiting periods for examination and grant, which discourages foreign participation and undermines confidence in India's patent ecosystem. Harmonization with the PCT requires not only alignment in legal texts but also improvements in procedural timelines and the overall capacity of the IPO.

Another procedural challenge stems from the differences in formal requirements for patent applications. The PCT encourages a standardized structure and formatting of patent applications, including the specification, claims, and abstract. However, India’s patent office applies its own scrutiny regarding the drafting style, clarity of claims, and sufficiency of disclosure. This sometimes leads to rejections or objections that would not occur in other jurisdictions. As a result, international applicants may find that their applications, although acceptable under the PCT or in other countries, require significant modifications to meet Indian standards. The lack of harmonization in formatting and evaluation guidelines creates procedural inconsistencies that hinder the goal of global patent uniformity.

India's insistence on working requirements for patents adds another layer of procedural complexity. Under Section 146 of the Indian Patent Act, patentees are required to submit periodic statements (Form 27) disclosing whether the patented invention is being worked (i.e., commercially exploited) in India. This requirement is unique and does not have a counterpart in the PCT framework. It creates an additional compliance burden for patent holders, especially foreign applicants, who may not have commenced operations in India within a short time after patent grant. The procedural requirement of filing Form 27, coupled with the risk of compulsory licensing or revocation for non-working, makes the Indian patent process significantly more burdensome than the procedures under the PCT.

Language and documentation requirements also pose considerable challenges. Although India accepts patent applications in English, certain procedural elements such as translations of the original international application, abstracts, or amended claims must be submitted precisely and timely. Errors in translation, missing documents, or inconsistencies in forms can lead to delays, objections, or even loss of patent rights. This is especially problematic for foreign applicants who may not be familiar with India's procedural norms. In contrast, the PCT encourages electronic filing and centralized documentation through WIPO's digital portals, reducing duplication and minimizing errors. Bridging this procedural gap requires India to further streamline and integrate its filing systems with PCT digital infrastructure.

The lack of full digital integration and system interoperability is another procedural challenge. Although the Indian Patent Office has adopted several online systems for filing and tracking applications, its integration with international platforms such as WIPO's PATENTSCOPE or ePCT remains partial. Applicants often have to manually coordinate between the PCT's systems and India's national e-filing portal, leading to confusion, missed deadlines, and inefficiencies. The limited interoperability hinders seamless transition from the international phase to the national phase of PCT filings, ultimately affecting the predictability and reliability of the patent process in India.

Procedural transparency and predictability also pose significant hurdles. Applicants, especially foreign entities, often face challenges in understanding the rationale behind office actions or examination reports issued by Indian patent examiners. While the PCT system is based on clear guidelines and uniform procedures across member countries, the Indian patent process is sometimes marked by subjective interpretation of claims and inconsistent application of rules. This unpredictability makes it difficult for applicants to plan their patent prosecution strategies and may discourage them from seeking protection in India through the PCT route.

The procedural challenge is further intensified by the lack of harmonized timelines and fee structures. While the PCT offers a relatively predictable cost structure for filing and prosecution, India's national phase involves multiple stages of fee payments, which vary depending on applicant type, number of claims, pages, and services availed. Additionally, amendments to rules or fee structures in India are not always promptly communicated or aligned with global practices, leading to confusion and missteps during prosecution.

International applicants must navigate this complex procedural terrain, which stands in stark contrast to the PCT's goal of simplicity and uniformity.

Capacity building and examiner training also remain critical procedural concerns. The Indian Patent Office must continuously train its personnel to understand international patent norms, classifications, and examination guidelines aligned with the PCT. Inadequate or inconsistent training can lead to variances in patent examination quality and procedural inefficiencies. As PCT filings bring in diverse and technically complex inventions, ensuring procedural competence among patent examiners is essential for smooth harmonization.

Lastly, the procedural enforcement mechanisms for granted patents also reflect a gap between Indian practices and global expectations. Although the PCT does not directly deal with enforcement, harmonization in procedures implies that granted patents should enjoy effective and timely legal protection. In India, the procedural enforcement of patent rights often involves long litigation timelines, lack of specialized patent benches in courts, and inadequate interim relief measures. These shortcomings indirectly affect the procedural credibility of the patent system and dissuade international applicants from actively enforcing or maintaining their patents in India.[11]

3.2 Economic Challenges in Harmonizing the Indian Patent Act with the Patent Cooperation Treaty (PCT)

Harmonizing the Indian Patent Act with the provisions of the Patent Cooperation Treaty (PCT) brings forth a range of economic challenges that affect multiple stakeholders, including the government, innovators, industries, and foreign investors. While the integration aims to streamline the patenting process and promote international collaboration, the economic implications of such harmonization must be carefully considered, especially in the context of a developing country like India. The fundamental economic challenge lies in balancing the global expectations of patent protection with India's need to ensure affordability, accessibility, and economic inclusivity.

[11] Ghosh, S. (2014). *Legal history of patent law in India*. Journal of Intellectual Property Law & Practice, 9(3), 213–220.
Kumar, N. (2010). *Technology and innovation in India: Challenges and policy options*. Science, Technology and Society, 15(1), 1–28.

One of the core economic challenges is the potential rise in the cost of accessing patented technologies. The PCT facilitates easier filing and enforcement of patents internationally, which can result in a surge of foreign patent applications in India. While this may enhance India's image as a key player in the global intellectual property ecosystem, it could also lead to an influx of foreign-owned patents in critical sectors such as pharmaceuticals, agriculture, and software. These sectors are vital to India's socio-economic development, and increased foreign patent ownership may result in higher licensing fees, restricted access to technology, and increased product prices, particularly in public health.

The pharmaceutical industry serves as a prominent example of how harmonization can lead to economic constraints. India has long been recognized as a global hub for affordable generic medicine. However, strict patent standards under international agreements like the PCT could reduce the window for generic entry, allowing multinational companies to maintain longer market exclusivity and charge premium prices. This not only increases healthcare costs for Indian consumers but also threatens the viability of India’s generic drug industry, which plays a critical role in global healthcare by supplying low-cost medicines to many developing nations.

Another economic challenge concerns the administrative and infrastructural investment required to implement PCT-aligned systems. Upgrading India’s patent administration to match PCT standards would involve significant spending on digital infrastructure, examiner training, system interoperability, and stakeholder education. For a resource-constrained government, diverting funds toward patent system upgrades might place additional pressure on other priority sectors such as education, healthcare, and rural development. While the long-term gains of a harmonized system could be substantial, the initial economic burden remains a key consideration.

Harmonization also raises concerns about the economic viability of micro, small, and medium enterprises (MSMEs). These enterprises, which form the backbone of India’s economy, often lack the financial and technical resources to navigate the complexities of an internationally harmonized patent regime. Filing under the PCT involves high application, translation, and legal costs. If Indian MSMEs are unable to afford the international patenting process, they risk losing out on global market opportunities and innovation protection. This economic

barrier may widen the gap between large corporations and smaller domestic innovators, potentially stifling grassroots innovation and economic equity.

Moreover, harmonization could result in a shift in R&D focus. Large corporations, especially multinational ones, may increasingly tailor their innovation strategies to comply with international standards rather than addressing local needs. This shift may divert investments away from India-specific problems, such as low-cost healthcare solutions or sustainable agriculture tailored to Indian climatic conditions. The economic consequence of such a trend would be a disconnect between the innovation ecosystem and the real needs of the Indian population, leading to inefficient allocation of resources and missed developmental opportunities.

The economic implications also extend to foreign direct investment (FDI). A harmonized patent regime aligned with the PCT is often viewed as a positive signal for foreign investors, as it promises stronger intellectual property protection. While this may attract increased FDI, especially in technology-intensive sectors, it could also give foreign firms a competitive edge over domestic players, leading to market domination and monopolistic practices. This dual-edged economic outcome must be managed through strategic policy measures that encourage FDI without undermining the competitiveness of local industries.

Another economic concern is the cost burden on individual inventors and academic institutions. Many Indian universities and individual researchers play a vital role in innovation but often lack the funding to file international patents. Under a harmonized system that aligns with PCT norms, these entities may struggle to bear the high costs associated with international filings, maintenance fees, and legal consultations. Consequently, valuable indigenous innovations may remain unprotected or underutilized, leading to economic losses in terms of potential commercialization and global recognition.

Patent harmonization also necessitates a recalibration of economic policies related to licensing, technology transfer, and commercialization. As the patent landscape becomes more globalized, Indian companies may be compelled to enter into licensing agreements with foreign patent holders, potentially resulting in royalty outflows and dependency on external technology. This shift could slow down domestic technological development and increase India’s economic vulnerability in strategic sectors.

In addition, harmonization brings challenges in terms of balancing innovation incentives with public interest. A PCT-compliant system may prioritize strong patent rights to attract global investors and corporations. However, this can limit the use of flexibilities like compulsory licensing, which India has utilized effectively to promote public welfare. Reducing these economic tools could weaken the government's ability to intervene in the market during emergencies, affecting sectors where affordability and access are critical, such as medicines and renewable energy.

Lastly, the dynamic nature of global trade agreements adds further complexity. Harmonizing with the PCT is not an isolated decision—it must also align with India's commitments under the World Trade Organization (WTO), Free Trade Agreements (FTAs), and other multilateral arrangements. The economic challenge lies in ensuring that the harmonized patent framework remains flexible enough to adapt to evolving international economic policies while safeguarding India's national interest and economic sovereignty.

While harmonizing the Indian Patent Act with the PCT offers significant advantages in terms of global integration and legal uniformity, it also presents considerable economic challenges. These include increased costs of innovation, barriers for MSMEs and local inventors, potential threats to public access in critical sectors, and the economic burden of systemic upgrades. For India, it is essential to adopt a cautious and balanced approach that fosters innovation and global participation without compromising affordability, inclusivity, and long-term economic sustainability. A well-strategized harmonization process must therefore integrate economic safeguards, domestic support systems, and equitable policies to ensure that the benefits of globalization do not come at the cost of national development.

3.3 Legal Challenges in Harmonizing the Indian Patent Act with the Patent Cooperation Treaty (PCT)

The harmonization of the Indian Patent Act (IPA) with the Patent Cooperation Treaty (PCT) has been a subject of intense legal scrutiny and policy debate. While the objective of harmonization is to ensure consistency in global intellectual property standards and facilitate international patent protection, the process presents several legal challenges that stem from

differences in legal principles, national interests, procedural norms, and constitutional obligations. India's unique socio-legal context, shaped by its commitment to public welfare and access to essential goods, further complicates this alignment with the PCT's largely commercial and protection-oriented framework.

One of the primary legal challenges lies in reconciling the fundamental objectives of the Indian Patent Act with those of the PCT. The Indian Patent Act, particularly after the 2005 amendment, incorporates provisions that are tailored to safeguard public health, promote affordable access to medicines, and ensure that patents are granted only for genuine innovations. Section 3(d) of the IPA, for instance, prevents the patenting of incremental innovations or minor modifications of known substances unless they result in enhanced efficacy. This provision is central to India's legal approach to preventing 'evergreening'—a practice often used by pharmaceutical companies to extend monopoly rights. However, the PCT system, while procedural in nature, does not restrict such patent applications, creating a legal tension when international applicants seek protection in India.

Another significant legal challenge is the interpretation and application of compulsory licensing under Indian law vis-à-vis the expectations of the PCT and related international instruments like TRIPS. The Indian Patent Act allows the government or third parties to issue compulsory licenses for patented inventions in situations involving public health emergencies, non-working of patents, or unaffordable prices. While such measures are in line with TRIPS flexibilities, PCT-aligned systems are often viewed through a lens of strong patent holder rights. Harmonizing the IPA with the PCT could invite pressure to dilute India's compulsory licensing provisions, potentially undermining legal tools crucial for maintaining public welfare.

The procedural divergence between Indian patent law and PCT norms also gives rise to legal complexities. For instance, while the PCT simplifies the process of filing a single international application, the granting of a patent remains the sovereign right of each nation. India's legal framework involves a detailed examination process, including strict scrutiny of novelty, inventive step, and industrial applicability under the Indian context. Legal alignment with the PCT must therefore preserve the integrity of India's patentability criteria while also conforming to the international procedural framework. Failure to strike this balance may either dilute India's legal standards or lead to conflicts in the interpretation of patent rights.

Legal challenges also emerge from the protection of traditional knowledge and biodiversity. The Indian Patent Act includes provisions that mandate disclosure of the source and geographical origin of biological material used in inventions. It also prohibits patents on inventions that are contrary to public order or morality. These legal provisions stem from India's obligations under the Convention on Biological Diversity (CBD) and the Biological Diversity Act, 2002. However, the PCT does not require such disclosures, creating a legal vacuum that can potentially be exploited by foreign applicants. Harmonizing the IPA with PCT standards without adequate safeguards may thus weaken India's legal stance against biopiracy and unauthorized use of indigenous knowledge.

A related legal concern pertains to the capacity of India's judicial and quasi-judicial bodies to manage an increase in patent-related disputes arising from international filings. As harmonization progresses, Indian courts may face a rise in litigation involving foreign entities and cross-border legal principles. The judiciary will need to interpret PCT-compliant laws while maintaining fidelity to the Indian legal ethos, which prioritizes public interest. This requires judicial training, development of IP-specialized benches, and uniform interpretation of international law—areas where India still faces institutional gaps.

Moreover, harmonization with the PCT requires alignment in legal language, definitions, and standards of legal interpretation. For example, terms such as "prior art," "inventive step," and "industrial applicability" may be interpreted differently across jurisdictions. The Indian Patent Office and legal professionals will need to ensure consistency in the interpretation of these terms to avoid legal uncertainty. Differences in language and terminology can lead to inconsistent decisions, legal disputes, and challenges to patent validity.

India's constitutional framework further adds to the legal complexity. Intellectual property is a subject under the Union List, meaning the central government has legislative power. However, any amendment to the IPA for harmonization purposes must align with constitutional principles such as the right to life (Article 21), which includes access to health and education. Overzealous harmonization that curtails access to essential goods could be challenged on constitutional grounds. Legal reform efforts must therefore be tested against constitutional benchmarks to ensure they do not infringe upon fundamental rights.

Legal predictability is another area of concern. Investors and innovators expect a stable and predictable legal environment for patent protection. Harmonization with the PCT may introduce new legal uncertainties if not accompanied by comprehensive legal reforms and capacity building. The lack of clarity in interpreting PCT procedures, timelines, and rights of applicants under Indian law could result in legal ambiguity, deterring both domestic and international inventors.

The issue of enforcement also presents legal challenges. While harmonization may result in greater conformity in granting patents, enforcing those patents across jurisdictions remains a daunting legal task. Differences in remedies, damages, injunctive relief, and judicial timelines make it difficult for patent holders to enforce rights in India in the same manner as they would in PCT-compliant countries. This asymmetry in legal enforcement undermines the objectives of harmonization and weakens the effectiveness of the patent regime.

Finally, legal challenges arise from resistance among domestic stakeholders. Legal harmonization with the PCT is not merely a technical process—it is a legal transformation that affects numerous stakeholders, including Indian companies, civil society organizations, legal professionals, and patent examiners. There may be legal opposition to reforms that are perceived to benefit multinational corporations at the cost of domestic interests. Addressing these legal apprehensions requires transparent legal reform processes, public consultations, and impact assessments to ensure that harmonization is inclusive and equitable.

3.4 Administrative Challenges in Harmonizing the Indian Patent Act with the Patent Cooperation Treaty (PCT)

Harmonizing the Indian Patent Act (IPA) with the Patent Cooperation Treaty (PCT) is a complex and multifaceted endeavor, particularly when viewed from an administrative perspective. Although such harmonization aims to create a more streamlined, efficient, and internationally consistent patenting process, it also introduces a series of administrative challenges that can significantly strain the existing infrastructure and institutional capacities of India's patent system.

One of the primary administrative challenges is the readiness and capacity of the Indian Patent Office (IPO). Harmonization requires that the IPO adhere to international standards in

processing, examining, and granting patents. However, the current system often faces issues such as understaffing, lack of technical experts, and delays in patent examinations. The increased volume of patent applications, especially from international applicants under the PCT route, would add further pressure on an already burdened system. Without adequate recruitment, training, and resource allocation, the IPO may struggle to deliver timely and high-quality patent examination services.

Training and upskilling of patent examiners is another crucial administrative hurdle. To properly evaluate PCT applications, examiners must be familiar with international standards, practices, and legal interpretations. Given that patent laws and technological domains are constantly evolving, there is a continuous need for skill enhancement. However, budgetary and logistical constraints often prevent the Indian patent system from investing adequately in human resource development. This gap can result in inconsistent or erroneous decisions, undermining the credibility of the patent system and deterring applicants.

Language and technical documentation pose additional administrative difficulties. PCT applications often come with detailed technical disclosures in multiple languages and formats. Ensuring accurate translations, understanding highly specialized technical jargon, and verifying claims require administrative precision and expertise. India's multilingual landscape adds complexity, especially when domestic applications are filed in regional languages, making harmonized processing even more challenging.

Another key administrative challenge is upgrading and maintaining the technological infrastructure of the patent system. Efficient implementation of the PCT framework demands robust digital platforms capable of handling international patent filings, tracking applications, and ensuring secure communication with the World Intellectual Property Organization (WIPO) and other patent offices. Although India has made progress in digitizing its patent system, technological inconsistencies, server downtimes, and cybersecurity vulnerabilities remain. These issues can disrupt the smooth functioning of a harmonized system and diminish user trust.

Coordination between national and international bodies also emerges as a significant administrative challenge. Harmonization requires seamless communication and data exchange between the IPO, WIPO, and other relevant institutions. Ensuring this coordination involves establishing standardized protocols, sharing databases, and maintaining regular liaison—a

task that demands a well-trained administrative workforce and efficient governance models. Any lapses in communication can lead to procedural delays, missed deadlines, and legal complications.

Public awareness and stakeholder engagement represent another important administrative dimension. Many Indian innovators, particularly those from small enterprises, academic institutions, and rural areas, are still unfamiliar with the PCT framework and its implications. The lack of targeted outreach and awareness programs hampers their ability to engage effectively with a harmonized system. Administratively, it becomes imperative for the government to design and implement extensive training, public education campaigns, and consultation initiatives to ensure that the benefits of harmonization reach all sections of society.

Furthermore, administrative rigidity and procedural formalities can act as barriers to efficient harmonization. India's patent bureaucracy is sometimes criticized for being overly procedural, with rigid documentation requirements and insufficient transparency in decision-making. Integrating PCT procedures into such a structure would require significant policy reform, simplification of processes, and a more applicant-friendly administrative culture. Without these reforms, the harmonized system may remain inefficient and inaccessible to many users.

Another administrative issue lies in monitoring and enforcing compliance with international norms. As India aligns with the PCT, it must ensure that all filings, decisions, and processes comply with international timelines and quality benchmarks. This requires establishing internal audit mechanisms, quality control standards, and performance indicators within the IPO and related administrative bodies. However, given the current limitations in administrative capacity, developing such oversight mechanisms presents a formidable challenge.

Budgetary constraints further complicate the administrative transition. Harmonizing with the PCT involves a significant financial outlay for infrastructure development, human resource expansion, digital platform upgrades, and international cooperation. Given competing demands on public finances—particularly in a developing country like India—allocating sufficient funds to patent administration may not always be prioritized. This financial limitation can hinder timely implementation and compromise the quality of administrative

services.

Finally, resistance to change within administrative institutions must be acknowledged. Organizational inertia, reluctance to adopt new practices, and lack of motivation among staff can delay or dilute the effectiveness of harmonization efforts. To overcome this, strong leadership, institutional restructuring, and change management strategies are required—elements that demand time, political will, and sustained administrative focus.

The administrative challenges in harmonizing the Indian Patent Act with the PCT are both deep-rooted and wide-ranging. They encompass issues of institutional capacity, human resources, digital infrastructure, coordination, public engagement, financial limitations, and bureaucratic culture. Addressing these challenges requires a comprehensive and phased approach that includes investment in training, modernization of infrastructure, simplification of procedures, and active stakeholder involvement. Only through such systemic reforms can India fully realize the benefits of a harmonized patent system while safeguarding national interests and promoting innovation across all segments of society.

CHAPTER 4 : COMPARATIVE ANALYSIS

In an increasingly interconnected global economy, intellectual property (IP) rights—particularly patents—play a vital role in fostering innovation, promoting economic development, and facilitating technology transfer. Countries around the world have developed distinct frameworks for managing patent protection based on their economic priorities, legal traditions, and alignment with international treaties. Brazil, South Africa, and China, though all members of the World Trade Organization and signatories to the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), have adopted varied approaches to patent law harmonization, influenced by their socio-economic needs and legal institutions. This comparative analysis explores the evolution, procedural mechanisms, legal systems, and challenges of harmonizing patent laws in these three countries, providing insights into how developing and emerging economies manage the balance between local interests and global obligations.[12]

4.1 Historical Background and Legal Evolution

Brazil's engagement with patent law dates back to the early 19th century, with its first law enacted in 1830. Over the years, the country oscillated between protectionist and liberal policies. Brazil's modern patent law is enshrined in Law No. 9.279/1996, commonly known as the Industrial Property Law. This legislation aligned Brazil with international IP standards and became a significant turning point in the country's patent regime. Prior to this, Brazil had excluded patents for pharmaceutical products and chemical compounds, but with TRIPS compliance, such exclusions were removed. This transition allowed foreign entities to protect inventions more robustly, though it also raised concerns about access to essential medicines and public health priorities.

In contrast, South Africa's patent law is grounded in the Patents Act 57 of 1978. One of the most distinctive features of South Africa's system is that it is a non-examining jurisdiction, meaning that patent applications are not substantively examined before being granted. The

[12] Reddy, T. (2014). *TRIPS implementation and public health: Lessons from India's patent policy*. Journal of Health Law and Policy, 5(2), 145–167.

patent office primarily checks for procedural compliance. While this approach streamlines the registration process and makes it cost-effective, it opens up possibilities for frivolous or low-quality patents being granted, potentially impacting the innovation ecosystem negatively. Despite these concerns, South Africa has participated in global IP frameworks such as TRIPS and the Patent Cooperation Treaty (PCT), signaling its intention to stay aligned with international standards.

China, over the past few decades, has rapidly evolved into a leading global player in patent filings. Its first patent law was promulgated in 1984, following economic reforms and the country's opening to foreign investment. Since then, China has revised its patent legislation multiple times—in 1992, 2000, 2008, and most recently in 2020—to enhance enforcement mechanisms and harmonize with international standards. The China National Intellectual Property Administration (CNIPA) oversees patent filings and examinations, and the country has adopted a rigorous system of substantive examination. China's legislative amendments reflect its strategic aim to become a global innovation leader, and the government has taken strong steps to encourage domestic innovation, including subsidies for patent applications and the establishment of specialized IP courts.

4.2 Filing and Examination Procedures

In Brazil, patent applications must be filed with the Instituto Nacional da Propriedade Industrial (INPI). Applications are subject to a thorough substantive examination, which may take several years to complete due to backlogs and capacity issues at the INPI. Applicants are required to request examination within 36 months of the filing date; failure to do so leads to abandonment. Additionally, third-party observations may be submitted during examination, allowing a level of public participation and transparency. Post-grant, patents may be challenged through administrative or judicial routes. The extensive examination process ensures higher quality patents but often causes significant delays.

South Africa's filing process is relatively straightforward. Patent applications are submitted to the Companies and Intellectual Property Commission (CIPC). Due to its non-examining nature, applications are granted without any investigation into their novelty, inventive step, or industrial applicability. While this allows faster registration and reduced costs, it transfers the burden of validating patent claims to the judicial system. Disputes about patent validity typically arise during litigation, which can be both time-consuming and expensive. South

Africa has been under pressure from civil society and international stakeholders to introduce a substantive examination system, especially in sectors such as pharmaceuticals, where low-quality patents can hinder access to affordable medication.

China offers a far more advanced and systematic approach to patent filing and examination. Applications filed with CNIPA undergo a detailed substantive examination, including prior art searches and technical scrutiny. Examination must be requested within three years from the filing date. China has also introduced several initiatives to expedite examination, including prioritized examination for high-tech sectors and streamlined procedures for patent reexamination and invalidation. With one of the largest patent offices in the world, China processes millions of applications annually and has developed extensive examiner training programs and digitized infrastructure to handle the volume efficiently.

4.3 Patentability and Subject Matter Exclusions

Brazil follows international norms for patentability—novelty, inventive step, and industrial applicability. However, certain subject matters remain excluded from patent protection. These include scientific theories, mathematical methods, purely abstract intellectual activities, and discoveries of natural substances. Notably, Brazil does not allow the patenting of methods of treatment or diagnosis, aligning with TRIPS flexibilities. The controversial Article 229-C of the Industrial Property Law mandates prior approval from the National Health Surveillance Agency (ANVISA) for pharmaceutical patents, creating an additional layer of administrative scrutiny and often leading to delays.

South Africa's law also mirrors standard patentability criteria. However, due to its non-examining system, the scrutiny of these requirements occurs post-grant if challenged. South African law excludes discoveries, scientific theories, mathematical methods, and methods for medical treatment from patent protection. The lack of a substantive examination mechanism means that such exclusions are often overlooked unless contested during litigation. The absence of rigorous patent screening continues to raise concerns about the system's vulnerability to abuse.

China's patent law sets out clear criteria for patentability, in alignment with global standards. The 2020 amendment further reinforced these criteria by improving guidelines for

pharmaceutical and biotech patents. However, China excludes specific categories such as scientific theories, methods for mental activities, and diagnostic or surgical methods. Additionally, inventions that are contrary to public morality or social order are unpatentable. China's evolving approach to patentability, especially in the pharmaceutical and tech sectors, indicates its responsiveness to both domestic innovation needs and global best practices.

4.4 Enforcement Mechanisms and Judicial Remedies

Enforcement of patent rights is a critical component of a functioning IP system. In Brazil, enforcement can be pursued through civil litigation, administrative proceedings, or criminal prosecution in cases of willful infringement. The judiciary, although relatively slow, is competent to handle patent disputes, and specialized IP courts exist in some regions. Brazil's commitment to TRIPS also ensures that remedies such as injunctions, damages, and seizure of infringing goods are available to patent holders.

South Africa provides for judicial enforcement of patent rights through the High Court. Patent litigation can be complex due to the lack of pre-grant examination, placing greater emphasis on expert testimony and judicial interpretation. While remedies include damages and injunctions, litigation is costly and slow, often inaccessible to small or medium enterprises. Additionally, South Africa lacks a specialized IP court, which affects the consistency and efficiency of patent dispute resolution.

China has made significant strides in patent enforcement by establishing specialized IP courts in major cities such as Beijing, Shanghai, and Guangzhou. These courts have played a vital role in increasing the speed and quality of IP judgments. China's 2020 amendments introduced punitive damages for willful infringement and expanded the scope for administrative enforcement. The dual-track enforcement system, involving both civil courts and administrative agencies, allows for flexible and efficient resolution of disputes. These reforms have contributed to increasing investor confidence in China's patent system.

4.5 Challenges and Criticisms

Brazil's patent system faces challenges such as examination backlogs, administrative inefficiencies, and a lack of technological expertise among examiners. The dual approval system for pharmaceutical patents has been criticized for delaying access to life-saving drugs.

Moreover, Brazil's use of compulsory licensing in specific situations—such as for HIV/AIDS medication—has sparked debate on balancing public health with IP rights. While the country strives to modernize its IP regime, bureaucratic obstacles continue to hamper efficiency.

In South Africa, the absence of substantive examination remains the most significant challenge. Civil society organizations have repeatedly called for reforms to prevent the abuse of the system, particularly by pharmaceutical companies. The government has proposed the introduction of a pre-grant opposition system and examination of patents in critical sectors. However, implementation has been slow due to financial and institutional constraints. The country also lacks a coherent national IP strategy that integrates health, innovation, and industrial policies effectively.

China, despite impressive legal reforms, still faces skepticism over enforcement consistency, especially in cases involving foreign companies. Allegations of favoritism toward domestic firms, issues related to trade secrets, and concerns over local protectionism persist. Moreover, the sheer volume of patent filings has raised questions about the quality of patents granted. While the government has taken measures to discourage "junk patents" and encourage high-quality filings, maintaining the integrity of the system remains a significant challenge.

4.6 Comparative Summary

In comparing these three nations, it is evident that each has taken a distinct path toward patent law development. Brazil has a robust legal framework with comprehensive examination procedures but struggles with administrative inefficiencies. South Africa offers a cost-effective but less reliable system due to the absence of substantive examination. China, on the other hand, has developed a sophisticated and rigorous patent regime supported by advanced infrastructure and judicial mechanisms.

Brazil's focus lies in balancing TRIPS compliance with public health and local industrial policy, while South Africa emphasizes accessibility and affordability, albeit at the cost of quality control. China's IP policy is deeply integrated into its economic development strategy, aiming to position itself as a global leader in innovation. The comparative analysis reveals that while harmonization with international treaties like TRIPS and the PCT is essential, national contexts heavily influence the design and effectiveness of patent systems.

The patent regimes in Brazil, South Africa, and China represent diverse approaches to managing intellectual property rights in emerging and developing economies. While all three countries share common goals of fostering innovation and protecting inventors, the means through which they achieve these goals differ based on historical legacies, economic priorities, and institutional capacities. For India and other developing countries looking to harmonize national patent laws with international standards, these three models offer valuable lessons. Brazil illustrates the importance of maintaining public interest within a global framework; South Africa highlights the risks of limited examination; and China demonstrates how proactive policy-making and institutional investment can create a strong IP ecosystem. As globalization continues to shape IP norms, the experiences of these countries will play a crucial role in shaping the future of global patent harmonization.

CHAPTER 5 : LEGAL FRAMEWORK AND JUDICIAL PRECEDENTS IN PATENTS ACT

5.1 Statutory Basis: The Patents Act, 1970

The central legislation governing patents in India is the **Patents Act, 1970**, which came into force on April 20, 1972. Initially crafted in response to the Ayyangar Committee Report (1959), the Act represented a move away from colonial patent systems that disproportionately favored foreign applicants. The 1970 Act allowed only process patents for pharmaceuticals and chemicals—a policy aimed at fostering the domestic generic industry.

However, following India's accession to the WTO and the TRIPS Agreement in 1995, the Act underwent three major amendments—in 1999, 2002, and 2005—to achieve compliance.

5.2 The TRIPS-Driven Amendments

a. The Patents (Amendment) Act, 1999

This amendment introduced a "mailbox" system to receive product patent applications for pharmaceuticals and agrochemicals, in line with Article 70.8 of TRIPS. It also provided Exclusive Marketing Rights (EMRs) under Article 70.9 for five years or until a product patent was granted.

b. The Patents (Amendment) Act, 2002

This amendment brought structural reforms, including the establishment of the Intellectual Property Appellate Board (IPAB), refinement of the definition of "inventive step," and adoption of international best practices. It expanded patentable subject matter and extended the patent term uniformly to 20 years, as required under Article 33 of TRIPS.

c. The Patents (Amendment) Act, 2005

This final amendment completed India's TRIPS obligations by allowing product patents

across all technological fields, including pharmaceuticals. It introduced post-grant opposition procedures and codified Section 3(d) to prevent the patenting of minor modifications to existing drugs unless they show significantly enhanced efficacy.

5.3 Key Legal Concepts in the Indian Framework

a. Patentable Subject Matter

Under Section 3 of the Patents Act, certain categories are expressly excluded from patentability, such as inventions contrary to public order or morality, methods of agriculture, and mere discoveries of scientific principles. Section 3(d) is particularly significant in rejecting evergreening attempts.

Section 3(d) of the Indian Patents Act was introduced to prevent the practice of evergreening, where companies apply for patents on minor modifications of existing drugs to extend the life of their monopoly on a product. The provision specifically states that new forms of known substances cannot be patented unless they show a significant enhancement in efficacy. This section is critical in balancing innovation and public health by ensuring that only genuine innovations in the pharmaceutical industry are rewarded with patents.

b. Inventive Step and Industrial Applicability

The 2002 amendment refined the definition of "inventive step" to include technological advance and/or economic significance, ensuring a higher standard for patent grants.

c. Opposition Mechanisms

India's patent law provides for both **pre-grant opposition** (Section 25(1)) and **post-grant opposition** (Section 25(2)), allowing public participation and increased scrutiny in the patenting process. Grounds include lack of novelty, obviousness, and non-compliance with disclosure obligations.

d. Compulsory Licensing

Under Section 84, compulsory licenses may be issued three years after the grant of a patent on several grounds, including non-availability of the patented product at a reasonably

affordable price. The 2012 *Natco Pharma v. Bayer* case marked a watershed moment when India's first compulsory license was granted for the cancer drug Nexavar.

5.4 Judicial Precedents

5.4.1 Novartis AG v. Union of India & Others (2013)

Novartis AG v. Union of India & Others (2013) is a landmark decision in the field of Indian patent law. The case revolves around the rejection of a patent application for a new form of the drug imatinib mesylate (beta crystalline form) by Novartis, a Swiss multinational pharmaceutical company, by the Indian Patent Office. The case raised significant questions regarding patentability, especially concerning pharmaceutical products, the interpretation of Section 3(d) of the Indian Patents Act, and the broader issue of public health versus intellectual property rights.

Background of the Case

In the early 1990s, Novartis developed imatinib mesylate, which was effective in treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors. Novartis later created a new crystalline form of this drug — the beta crystalline form — which showed better physical properties like increased stability and easier storage. Novartis sought to patent this new form in India in 1998, but due to India's patent regime at the time, only process patents for pharmaceuticals were granted.

With the introduction of product patents under the 2005 amendment to the Indian Patents Act, Novartis filed for a patent on its beta crystalline form. However, the application was rejected on the grounds that it did not meet the standards of patentability as set out in Section 3(d) of the Indian Patents Act, which aimed to prevent "evergreening" — a practice of patenting minor modifications of existing drugs.

Novartis's Legal Challenge

In response to the rejection of its patent application, Novartis filed a writ petition in the Madras High Court. The company contended that Section 3(d) was unconstitutional and violated the principles of TRIPS (Trade-Related Aspects of Intellectual Property Rights) by imposing arbitrary restrictions on patentability. Novartis also argued that the beta crystalline form of imatinib mesylate was a genuine innovation with enhanced therapeutic efficacy.

The Madras High Court upheld the validity of Section 3(d), recognizing that it was in line with India's constitutional mandate to promote public health and access to affordable medicines. Unhappy with the result, Novartis appealed to the Supreme Court of India.

Supreme Court's Judgment

The Supreme Court of India delivered its judgment on April 1, 2013, and rejected Novartis's appeal. The Court concluded that the beta crystalline form of imatinib mesylate did not meet the threshold of "enhanced therapeutic efficacy" required under Section 3(d). While Novartis demonstrated that the new form had better physical properties, the Court emphasized that Section 3(d) focused on therapeutic efficacy — not just physical or chemical properties.

The judgment clarified that for a new form of a known substance to be patented, it must offer a significant and substantial therapeutic benefit, rather than simply being a marginal improvement in the physical form of the substance.

Interpretation of "Efficacy"

One of the most critical aspects of the Supreme Court's judgment was the interpretation of the term "efficacy" under Section 3(d). The Court ruled that efficacy in this context refers specifically to therapeutic efficacy, which means a measurable improvement in the drug's therapeutic effect. It rejected the argument that enhanced stability or bioavailability alone would suffice to meet the standard for patentability.

This interpretation effectively curbed the practice of pharmaceutical companies patenting minor modifications that did not contribute to the drug's therapeutic benefits. The ruling aimed to prevent patents from being granted on incremental innovations that did not offer substantial improvements in the treatment of diseases.

Impact of the Judgment on Indian Patent Law

The Supreme Court's judgment in the Novartis case has far-reaching implications for India's patent law and its approach to public health. The decision affirmed India's commitment to ensuring that patent laws serve public health interests by allowing the continued production and distribution of affordable generic medicines. This was particularly significant for drugs like imatinib, which are essential for the treatment of cancer, a disease that places a massive financial burden on patients.

By rejecting Novartis's patent application, the Court ensured that Indian generic manufacturers could continue producing affordable versions of imatinib, which were sold at

a fraction of the price of the patented drug. This helped maintain access to life-saving medications for millions of people, not just in India, but also in developing countries around the world.

Global Reactions to the Judgment

The judgment was met with mixed reactions globally. Public health advocates and supporters of affordable medicines lauded the decision, viewing it as a victory for access to life-saving drugs. The case highlighted the need to balance intellectual property rights with the global public health challenge of ensuring access to medicines in poorer nations.

On the other hand, multinational pharmaceutical companies and industry groups expressed concerns about the decision, arguing that it could discourage innovation in the pharmaceutical industry. They feared that the ruling might lead to reduced patent protections in India, undermining incentives for research and development of new drugs.

However, the Supreme Court's judgment was consistent with India's obligations under the World Trade Organization's TRIPS Agreement, which allows countries to implement provisions that protect public health, especially in cases where patented drugs are unaffordable.

Role of Public Health in Patent Decisions

A significant feature of the Novartis case was the Court’s emphasis on public health as a paramount concern in the interpretation of patent law. The ruling highlighted the necessity of ensuring that patent protection does not hinder the availability of affordable medicines, particularly in developing countries where the healthcare needs are vast and resources are limited.

India’s patent regime, as affirmed by the Court, seeks to strike a balance between encouraging innovation and ensuring access to affordable healthcare. By rejecting Novartis's application, the judgment reinforced the idea that patent laws should not be used to extend monopolies on life-saving drugs that are essential for public health.

Impact on the Indian Generic Drug Industry

The Supreme Court's decision was a boon for India's generic pharmaceutical industry, which is one of the largest in the world. India is often referred to as the "pharmacy of the developing world" because of its ability to produce and export affordable generic medicines to countries around the globe. This ruling preserved the ability of Indian generics manufacturers to continue producing affordable versions of essential drugs like imatinib, thus ensuring access to life-saving treatments for patients who could not afford the branded versions.[13]

5.4.2 Bayer Corporation v. Union of India & Natco Pharma Ltd. (2014): A Milestone in Compulsory Licensing

The case of *Bayer Corporation v. Union of India & Natco Pharma Ltd.* (2014) is a seminal judgment in Indian patent jurisprudence, particularly concerning the concept of **compulsory licensing**. It marked the first time that the Indian Patent Office issued a compulsory license under Section 84 of the Indian Patents Act, 1970. The case involved Bayer's patented drug Nexavar, used for treating liver and kidney cancer, and Natco Pharma's request to manufacture a generic version at a lower price. This case brought global attention to India's patent regime and emphasized its pro-public health stance. It underlined how patent law can serve as a tool not just for protecting innovation but also for ensuring affordable access to life-saving medications.

Background of the Dispute

Bayer Corporation, a multinational pharmaceutical giant, held an Indian patent for sorafenib tosylate, marketed under the brand name Nexavar. The drug was used in the treatment of advanced-stage liver and renal cancers and was priced at approximately INR 2.8 lakh (about USD 5,000) for a month's dose, making it unaffordable for most Indian patients. Recognizing this, Natco Pharma, an Indian generic drug manufacturer, approached the Indian Patent Office in 2012 to seek a compulsory license for manufacturing and selling a more affordable version of the drug.

Under Section 84 of the Indian Patents Act, a compulsory license can be granted after three

[13] Novartis AG v. Union of India, Civil Appeal No. 2706–2716 of 2013 (Supreme Court of India).

years of the patent being granted if the reasonable requirements of the public are not met, the product is not available at a reasonably affordable price, or the patented invention is not worked in the territory of India. Natco argued that Bayer had failed on all three fronts, and after a thorough examination, the Controller General of Patents agreed and granted Natco the compulsory license.

Grounds for Granting Compulsory License

The Indian Patent Office cited three main reasons for granting the license to Natco. First, Bayer had not made the drug available to the majority of the population, thereby not meeting the reasonable requirements of the public. Second, the price of the drug was far beyond the reach of the average Indian, making it unavailable at a "reasonably affordable price." Third, Bayer was importing the drug into India in limited quantities instead of manufacturing it locally, thus failing to "work the patent" in the Indian territory.

These findings were consistent with the objectives of India's patent law, which aims to balance the exclusive rights of patentees with the broader goal of making essential drugs accessible and affordable to the public. Natco was ordered to pay Bayer 6% of its net sales as royalties and was required to sell the drug only through licensed distributors and medical institutions while maintaining strict quality standards.

Bayer's Legal Challenge

Unhappy with the grant of the compulsory license, Bayer challenged the decision before the Intellectual Property Appellate Board (IPAB). The company argued that it was still meeting the demand to the extent possible and that the concept of "working the patent" should not mandate local manufacturing. It further claimed that the price should not be the sole criterion for issuing a compulsory license and that this move undermined its R&D investments and violated the spirit of the TRIPS agreement under the WTO framework.

However, the IPAB upheld the decision of the Patent Office, stating that Bayer's pricing was unaffordable for most Indians and that the company had indeed failed to meet the reasonable requirements of the public. Bayer subsequently took the matter to the Bombay High Court and later to the Supreme Court of India, but the verdict remained in favor of the Indian authorities and Natco Pharma.

Public Health and Affordable Access

The case became a powerful illustration of India's emphasis on public health over commercial

monopolies. The compulsory license allowed Natco to produce a generic version of Nexavar for just INR 8,800 per month — less than 3% of Bayer's price. This drastic price cut made the drug accessible to thousands of patients who previously could not afford treatment. Public health advocates hailed the decision as a triumph for the right to health and access to medicine. The ruling reinforced India's global reputation as the "pharmacy of the developing world." By exercising the provisions of the Patents Act, India demonstrated that it was possible to comply with international intellectual property obligations while safeguarding domestic health concerns.

Legal Interpretation of "Reasonable Requirements"

A critical point in this case was the interpretation of what constitutes "reasonable requirements of the public." The authorities concluded that the limited distribution and high pricing of Nexavar by Bayer clearly failed to satisfy these requirements. The ruling clarified that a patented invention must not only be available in the market but should also be **affordable and accessible** to the general public.

This interpretation emphasized the utilitarian purpose of patents — to benefit the public through innovation. When innovation is priced out of reach, the law must step in to restore balance. By invoking Section 84, the Indian authorities sent a strong message that patents cannot be hoarded at the cost of public suffering.

Interpretation of "Working the Patent" in India

The judgment also clarified what it means to "work the patent" in India. Bayer's practice of importing small quantities of the drug rather than manufacturing it locally was deemed insufficient. The authorities ruled that merely making a patented product available through importation is not enough if it is not accessible or affordable to the people who need it.

The insistence on local manufacturing (or substantial local availability at reasonable prices) aligns with the purpose of patents — incentivizing innovation that benefits the domestic population. The decision laid down a clear benchmark for future patent holders in India, particularly in essential sectors like healthcare.

Global Implications and Industry Response

This case drew significant global attention, especially from pharmaceutical companies and international trade bodies. While access-to-medicine groups and health activists applauded India's move, multinational drug companies saw it as a threat to intellectual property rights.

They feared that compulsory licensing could become the norm in India and other emerging markets, undermining their business models and reducing incentives for innovation.

Despite these concerns, the Indian government maintained that its laws were fully compliant with the TRIPS agreement, which permits compulsory licensing under certain conditions, especially during public health crises. The case established a precedent and was closely followed by other countries exploring the use of compulsory licensing for expensive patented drugs.

Impact on Future Patent Litigation

The *Bayer v. Natco* case has had a lasting impact on the Indian patent landscape. It opened the door for more applications for compulsory licenses, particularly for drugs treating chronic or terminal illnesses. Although few such licenses have been granted since then, the case remains a key reference point for courts, patent offices, and policymakers.

It also influenced pharmaceutical companies to reconsider their pricing and distribution strategies in India. Some firms began offering tiered pricing models or voluntary licenses to generic manufacturers to avoid potential compulsory license applications.[14]

5.4.3 Roche v. Cipla (2009): A Landmark Judgment on Patent Enforcement and Public Interest

Introduction

The case of *F. Hoffmann-La Roche Ltd. & Anr. v. Cipla Ltd.* (2009) stands as a landmark in Indian patent litigation, especially for pharmaceutical patent enforcement and the interface between intellectual property rights and public interest. This case was the first of its kind where a multinational pharmaceutical giant sued an Indian generic manufacturer over an alleged infringement of a product patent under the Indian Patent Act, post-2005 TRIPS-compliant amendments. It raised fundamental questions about how patent rights are to be enforced in India, what constitutes infringement, and the extent to which public interest can affect enforcement of patent monopolies.

Background of the Case

The dispute revolved around a patented drug named Erlotinib Hydrochloride, marketed

[14] Bayer Corporation v. Union of India & Natco Pharma Ltd., (2014). *Supreme Court of India*.

globally by Roche under the brand name “Tarceva.” The drug is used in the treatment of non-small cell lung cancer (NSCLC), a disease that afflicts a significant portion of the Indian population. Roche was granted a product patent for Erlotinib in India in 2007. Soon after, Cipla, a prominent Indian pharmaceutical company, announced plans to launch a generic version of the same drug at a fraction of the cost. This prompted Roche to initiate a lawsuit against Cipla in the Delhi High Court, alleging patent infringement and seeking an injunction to restrain Cipla from manufacturing and marketing the generic drug.

Claims and Defenses

Roche claimed that Cipla’s generic version of Erlotinib violated its patent rights and that such infringement would cause it irreparable harm. Roche sought an ad-interim injunction to prevent Cipla from continuing its activities during the pendency of the lawsuit. On the other hand, Cipla defended itself on multiple grounds. Firstly, it challenged the validity of Roche’s patent on the grounds of lack of novelty and inventive step. Secondly, it invoked public interest, arguing that the generic version was significantly cheaper and critical for access to life-saving treatment for Indian patients.

Cipla’s legal team emphasized that Tarceva was priced at approximately INR 1.4 lakh per month, while Cipla’s version was available for less than INR 30,000 per month. The stark difference in price made Cipla’s version far more accessible to the Indian public. Cipla further argued that Roche’s enforcement of its patent would effectively deny affordable cancer treatment to the vast majority of patients in India.

Delhi High Court's Decision

The Delhi High Court delivered a nuanced judgment that carefully balanced the enforcement of patent rights with broader public interest. The Court declined to grant the interim injunction sought by Roche. While it acknowledged that Roche had a valid patent, it held that Cipla’s arguments concerning public interest could not be ignored. Justice Bhat, who delivered the judgment, stated that if the injunction were granted, it would irreparably harm cancer patients who depended on the cheaper alternative provided by Cipla.

The court noted that, in the balance of convenience, public interest in access to affordable medication outweighed Roche’s commercial interest in enforcing its monopoly rights. It made clear that Indian patent jurisprudence must evolve within the country’s socio-economic context and cannot mimic Western enforcement practices. This decision significantly highlighted the Indian judiciary’s intent to interpret patent law in a way that does not

compromise public health and access to essential medicines.

Significance of "Public Interest"

One of the most important contributions of this case to Indian patent law was the detailed analysis and emphasis on **public interest** as a crucial factor in deciding whether or not to grant an injunction. The court adopted a holistic approach by recognizing that intellectual property rights, although essential for innovation, must not be wielded in a manner that harms the larger public interest — particularly when it comes to healthcare.

The court invoked Section 83 of the Indian Patents Act, which lays down general principles applicable to the working of patented inventions in India. It states that patents are granted not merely to enable patentees to enjoy monopolies but also to ensure that the patented invention is worked in India and made available at reasonable prices. Roche v. Cipla thus firmly embedded public interest into the framework of patent enforcement in India, establishing that rights are not absolute and can be moderated in favor of public good.

Patent Validity Challenge

Another key element of the case was Cipla's challenge to the validity of Roche's patent. Cipla argued that the claimed compound lacked novelty and inventive step, particularly given that a closely related compound had already been disclosed in a prior application by Roche itself. While the Delhi High Court did not conclusively decide the issue of validity at the interim stage, it allowed this line of argument to continue as part of the trial, keeping the door open for a later determination.

This approach underlined the importance of substantive patent examination and the need to avoid granting monopolies on drugs that do not genuinely meet the standards of novelty and inventiveness. The court's openness to a validity challenge sent a strong message that patents in India would not be upheld merely based on formal grants but must pass the test of rigorous scrutiny in line with the objectives of public health and technological advancement.

Impact on Patent Enforcement in India

The judgment had significant ramifications for patent enforcement strategies in India. It warned multinational pharmaceutical companies that Indian courts would not automatically issue injunctions against generic manufacturers. Instead, courts would assess the broader impact of enforcement on public welfare. This approach shifted the focus from absolute protection of patent rights to a more balanced framework that considers affordability,

accessibility, and the socio-economic conditions of the Indian populace.

As a result, pharmaceutical companies became more cautious in litigating against Indian generic firms. The case prompted a broader dialogue within the industry about the ethics of drug pricing and the importance of voluntary licensing arrangements or tiered pricing strategies in developing countries.

Post-Judgment Developments

After the interim decision, the case proceeded to trial. Roche continued to pursue the matter, and the Delhi High Court in 2012 eventually ruled that Cipla had indeed infringed the patent, but by that time, significant changes had occurred in the pharmaceutical market, and the damage to Roche's monopoly had already been done. Moreover, the court reiterated that a mere patent grant does not entitle a party to an injunction — especially in sectors involving public health.

The decision also triggered similar arguments in subsequent cases, including those involving drugs for HIV, Hepatitis, and other serious diseases, where generic manufacturers cited *Roche v. Cipla* as a precedent to defeat or resist injunctions based on affordability and public interest.

Legal and Ethical Dilemmas

This case also brought to the forefront important legal and ethical questions. Should patent holders be allowed to charge exorbitant prices for life-saving drugs in developing countries? How does one reconcile the incentives for innovation with the moral imperative of providing treatment to those in need? The court did not offer definitive answers but set the tone for a more context-sensitive application of patent law in India.

Furthermore, it sparked debates on how TRIPS-compliant countries like India can navigate their obligations while also defending domestic priorities. The case reinforced India's position as a pro-public health jurisdiction, willing to interpret international obligations in a manner consistent with local realities and constitutional goals.

The *Roche v. Cipla (2009)* case represents a turning point in Indian patent law, especially in the context of pharmaceutical litigation. It is a powerful illustration of how Indian courts seek to harmonize intellectual property protection with public health imperatives. The ruling advanced the concept of patent law as a social contract — not an absolute right — that must serve broader national interests, particularly in the context of life-saving medications.

By prioritizing public interest over commercial monopolies, the judgment laid the

groundwork for a uniquely Indian jurisprudence on patent enforcement, one that respects innovation but also defends access. It encouraged policymakers, judges, and legal practitioners to think more deeply about how law can serve justice in both economic and human terms. The legacy of the *Roche v. Cipla* case continues to shape the contours of patent enforcement and access to medicine debates in India and across the developing world.[15]

5.4.4 TVS Motor Company Ltd. v. Bajaj Auto Ltd. (2009): Patent Enforcement and Innovation in the Indian Automobile Industry

Introduction

The *TVS Motor Company Ltd. v. Bajaj Auto Ltd.* case is a landmark in the context of Indian patent litigation, especially concerning mechanical and automotive innovations. It brought into focus the enforcement of patent rights within a competitive industry and addressed complex questions on infringement, innovation protection, and the role of injunctions in ongoing technological disputes. This case involved two Indian automobile giants and had long-term implications for patent jurisprudence in India, particularly in how courts balance innovation incentives against fair competition.

Background of the Case

Bajaj Auto Ltd., one of India's largest two-wheeler manufacturers, held a patent (No. 195904) for a technology related to an improved internal combustion engine using Digital Twin Spark Ignition (DTSi) technology. This innovation was aimed at improving engine efficiency and reducing emissions. In 2007, Bajaj filed a suit for patent infringement against TVS Motor Company, claiming that TVS's new motorcycle model, 'Flame,' used a similar twin-spark plug technology, which violated their patent.

TVS denied the infringement and countered by asserting that their engine technology was distinct and had been developed independently. They argued that the twin-spark plug mechanism was not novel or unique to Bajaj and was already in the public domain through prior art. The matter thus escalated into a highly contested patent dispute, drawing attention from the legal, automotive, and innovation communities.

Legal Issues Raised

[15] F. Hoffmann-La Roche Ltd. & Anr. v. Cipla Ltd., (2009). *Delhi High Court*.

The primary issue before the court was whether TVS Motor had infringed upon Bajaj Auto's patent and whether Bajaj was entitled to interim relief in the form of an injunction. The secondary questions included:

Whether Bajaj's patent was valid and enforceable

Whether TVS's technology was substantially similar to that of Bajaj

The extent to which an interim injunction could affect competition and innovation in the automobile sector

TVS challenged the validity of Bajaj's patent on the grounds of lack of novelty and inventive step, citing global patent literature. They also pointed out that twin-spark technology existed prior to Bajaj's filing. Bajaj, in response, claimed that their specific application of this technology within a two-wheeler engine was unique and had not been anticipated before.

Interim Injunction and Supreme Court Proceedings

In January 2008, a Division Bench of the Madras High Court granted an interim injunction restraining TVS from manufacturing and selling the 'Flame' motorcycle using the contested twin-spark plug technology. This led TVS to appeal to the Supreme Court of India.

The Supreme Court, in a significant order, lifted the injunction but laid down that TVS must maintain detailed records of production and sales, subject to the outcome of the case. The Court stressed the importance of allowing innovation and fair competition to continue while legal questions were being adjudicated. This intervention struck a balance between protecting IP rights and preventing undue market restrictions during ongoing litigation.

Patent Validity and Infringement Evaluation

The heart of the matter lay in evaluating whether Bajaj's DTSi patent met the essential requirements of novelty, inventive step, and industrial application. Bajaj argued that while spark ignition was known, their particular configuration and method of controlling the spark system in the combustion chamber was novel and provided superior engine performance.

TVS, on the other hand, cited prior art from international patents and publications, including those in the automobile and aviation industries, suggesting that the use of dual spark plugs was already known and widely used. TVS also claimed that their configuration was structurally different and did not infringe upon Bajaj's specific claims.

The court was faced with the complex task of interpreting technical claims in the patent specification and comparing them with the allegedly infringing product — a process that required detailed evidence and expert analysis.

Doctrine of Equivalents and Functional Similarity

One of the critical aspects the court examined was whether TVS's engine, though not an exact copy of Bajaj's technology, functioned in a substantially similar manner. The doctrine of equivalents allows a finding of infringement even if the accused product or process does not fall within the literal scope of the claims, but performs substantially the same function in substantially the same way to achieve the same result.

TVS argued that their combustion system used a unique configuration of swirl technology, which distinguished it from the DTSi design. Bajaj contended that the fundamental feature — two spark plugs working simultaneously for better combustion — was the same. The Court needed to assess whether the differences were material enough to avoid infringement under Indian patent law.

Outcome and Settlement

Although the case continued for several years, the matter was eventually settled out of court in 2010. The companies agreed to withdraw all pending litigations against each other, and the terms of the settlement were kept confidential. This resolution brought an end to one of India's most high-profile patent disputes in the automobile sector.

Despite the settlement, the case had already contributed significantly to the development of Indian patent law, especially in terms of:

- Judicial approach to interim injunctions in patent disputes
- The evaluation of prior art and inventive step
- Interpretation of technical patent claims by the courts
- Encouraging alternative dispute resolution in commercial IP cases

Implications for Patent Law and Industry

The Bajaj-TVS case served as a wake-up call for Indian industry players regarding the strategic importance of IP protection and litigation readiness. It underscored the need for companies to invest in R&D, file robust patent applications, and conduct thorough patent searches to avoid infringement claims.

For the judiciary, the case demonstrated the challenges of adjudicating technologically complex patent disputes and emphasized the importance of evidence-based trial procedures and expert testimony. It also encouraged courts to exercise caution before granting injunctions that could unfairly hinder business operations.

The case also pushed policymakers and stakeholders to consider reforms in the Indian patent litigation system — especially with regard to the fast-tracking of disputes in innovation-driven industries such as automotive, electronics, and pharmaceuticals.

The *TVS v. Bajaj* case stands out as a milestone in Indian patent litigation history. It not only tested the boundaries of mechanical patent enforcement but also demonstrated the competitive dynamics of Indian manufacturing sectors. The case highlighted how patent rights, while crucial for innovation, must be enforced with due regard to public interest and fair market competition.

In the broader context, the case signaled a maturing of India's IP ecosystem, where domestic players were no longer just licensees but creators and defenders of indigenous innovations. It also showcased the evolving judicial approach that balances innovation protection with market realities, setting a precedent for future technology-related patent disputes in India.[16]

[16] Indian Patents Act, 1970. (1970). *Government of India*.

Chapter 6: Harmonization Challenges and Indian Imperatives

In the contemporary era of globalization, where legal issues increasingly transcend national borders, it is crucial for every nation to ensure that its intellectual property rights (IPR) framework aligns with international best practices (WIPO, 2023). India, with its rich legal heritage based on common law, is no exception. While the Indian IPR regime has evolved significantly since independence (Kumar, 2018), there is a growing need to learn from global jurisprudence to harmonize patent laws (TRIPS Agreement, 1994), improve judicial efficiency in IPR cases (Singh, 2020), and ensure robust protection for creators and innovators (UNCTAD, 2021). This essay explores lessons India can draw from international jurisprudence and legal practices related to IPR, focusing on effective adaptation and implementation within the Indian legal context.[17]

6.1 Importance of Judicial Precedents and Predictability in IPR

Judicial precedents are fundamental to a strong IPR system. Countries like the United States and the United Kingdom have established consistent legal doctrines through precedents, particularly in patent law and copyright disputes. This consistency fosters innovation by providing clear legal expectations for businesses and inventors.

While Article 141 of the Indian Constitution mandates that Supreme Court decisions are binding, lower courts sometimes deviate from these rulings, leading to unpredictability. Strengthening the consistent application of IPR precedents through centralized databases, legal education reforms, and enhanced judicial training can foster greater legal stability and confidence among innovators.

6.2 Rights-Based Approach from European IPR Jurisprudence

European nations, guided by institutions like the European Court of Justice (ECJ), adopt a balanced, rights-based approach to IPR, ensuring that protection of intellectual property does

[17] World Intellectual Property Organization (WIPO). (2023). *Patent Cooperation Treaty (PCT) – General information*. https://www.wipo.int/pct/en/

not disproportionately infringe on public interest. The doctrine of proportionality plays a key role in balancing private rights with societal needs, especially in areas like data protection, copyright exceptions, and pharmaceutical patents.

India can benefit from adopting a structured application of this principle, particularly when handling conflicts between IPR enforcement and access to knowledge, medicines, and digital content. This would ensure that IPR laws serve both economic development and public welfare.

6.3 Legal Realism and Access to IPR Justice

Countries such as South Africa and Canada emphasize legal realism, ensuring that IPR laws serve not just corporate interests but also the broader public. They provide robust legal aid for small inventors and startups, ensuring equitable access to IPR protection mechanisms.

India's Intellectual Property Appellate Board (IPAB) was a step in this direction, but access to affordable legal assistance in IPR disputes remains limited. Drawing from Canada's inclusive model, India can decentralize legal aid for IPR cases, enhance funding, and deploy technology to support smaller entities in protecting their intellectual creations.

6.4 Efficient IPR Dispute Resolution through ADR Systems

Alternative Dispute Resolution (ADR) mechanisms, such as mediation and arbitration, are widely used in countries like Singapore and the US to resolve IPR disputes efficiently. Singapore's mediation centers handle complex IP cases swiftly, reducing litigation costs and delays.

India's Arbitration and Conciliation Act provides a framework for ADR, but its application in IPR matters is underutilized. Institutionalizing ADR for IPR disputes, with specialized mediators and arbitrators, can expedite resolutions, reduce case backlogs, and foster a more innovation-friendly ecosystem.

6.5 Judicial Accountability and Transparency in IPR Adjudication

Judicial accountability ensures fair and impartial IPR adjudication. The UK's Judicial Appointments Commission (JAC) and the US's public vetting processes promote

transparency and meritocracy.

India's collegium system for judicial appointments has faced criticism regarding opacity, which can affect IPR case outcomes. Establishing an independent commission for judicial appointments in IPR-related tribunals and courts, with clear criteria for selecting judges with expertise in IPR law, can enhance credibility and public trust.

6.6 Incorporation of International IPR Standards

Countries like South Africa incorporate international treaties such as TRIPS (Trade-Related Aspects of Intellectual Property Rights) directly into domestic law, ensuring consistency with global norms.

India, while TRIPS-compliant, often faces criticisms related to inconsistent enforcement and legislative gaps. Proactively aligning domestic IPR laws with evolving international standards, especially concerning digital rights, biotechnology patents, and traditional knowledge, can strengthen India's global IPR standing.

6.7 Patent Law Harmonization and TRIPS Compliance

Brazil and China have successfully balanced TRIPS compliance with national interests. Brazil's use of compulsory licensing ensures affordable medicines without breaching international obligations.

India's Section 3(d) of the Patent Act, which prevents evergreening, exemplifies this balance. However, enhancing the efficiency of patent examination processes, while maintaining safeguards for public health, can further harmonize India's patent regime with global standards and encourage foreign investments in R&D.

6.8 Technology and E-Governance in IPR Processes

Estonia's e-governance model showcases the benefits of digitization in legal systems. Its e-court system improves efficiency, transparency, and access to justice.

India's IPR digital platforms have advanced post-pandemic, but gaps remain in digital literacy and infrastructure. Expanding e-filing systems, virtual hearings for IPR disputes, and online

patent and trademark searches can significantly enhance efficiency and reduce procedural delays.

6.9 Specialized IPR Courts for Complex Issues

Countries like Germany and the US have specialized IP courts handling technical disputes, ensuring nuanced understanding and faster rulings.

India’s commercial courts handle IPR cases, but the absence of specialized IP benches leads to inconsistent decisions. Establishing dedicated IPR courts with judges trained in patent law, copyrights, and trademarks can improve decision quality and reduce litigation timelines.

6.10 Global Best Practices in IPR and Sustainable Development

International bodies like WIPO promote integrating IPR with sustainable development goals (SDGs), encouraging innovation that benefits society and the environment.

India’s IPR policies can adopt such frameworks, incentivizing green technologies, traditional knowledge protection, and inclusive innovation. Strengthening enforcement mechanisms and fostering global collaborations can position India as a leader in sustainable intellectual property development.

CHAPTER 7 : CONCLUSION AND RECOMMENDATIONS

The harmonization of the Indian Patent Act (IPA) with the framework and operational ethos of the Patent Cooperation Treaty (PCT) presents a multifaceted legal, economic, procedural, and institutional challenge that is deeply rooted in the very nature of India's socio-economic priorities, public health imperatives, and development goals. Over the years, India has demonstrated a careful and often cautious approach to integrating its patent law with international obligations, striking a balance between encouraging innovation and safeguarding national interests. However, with the increasing globalization of trade, technology, and intellectual capital, this balancing act is becoming more complex, necessitating a detailed understanding and deliberate action towards coherent harmonization with the PCT system.

The Patent Cooperation Treaty, administered by the World Intellectual Property Organization (WIPO), aims to streamline the process of filing patents internationally through a unified procedure. Its key advantage lies in offering applicants a single entry point for filing patent applications in multiple jurisdictions. While India is a contracting state to the PCT and has implemented certain procedures in line with it, the complete harmonization of the Indian Patent Act with the PCT's objectives, processes, and expectations remains a work in progress. The gap arises from India's distinct constitutional mandate, its socio-legal commitment to affordable healthcare, and its prioritization of public interest over commercial monopolies.

At the legal level, India's patent jurisprudence has traditionally been built around protecting public welfare. Provisions such as Section 3(d) of the Indian Patent Act, which restricts patentability of incremental innovations or mere modifications of known substances, have been instrumental in curbing practices such as "evergreening"—where pharmaceutical companies seek to extend patent monopolies by making minor alterations to existing drugs. While this provision aligns with national health policy and the need for affordable medicines, it often creates tension with international patent applicants who are accustomed to more liberal standards of patentability in other jurisdictions. Thus, harmonization with PCT norms, which may allow broader claims, would require a sensitive recalibration of Indian patent laws without undermining the fundamental safeguards embedded in them.

Procedurally, India has faced several hurdles in streamlining its patent administration to fully align with PCT processes. While India's patent offices have made significant strides in digitization, capacity-building, and timeliness, challenges remain in terms of manpower shortages, examiner training, and standardized quality of examinations. The International Search Report (ISR) and International Preliminary Examination Report (IPER), which are key components of the PCT process, require a highly skilled technical workforce that can perform substantive examination efficiently. Despite improvements, Indian patent offices need further capacity enhancement to meet the expectations of uniformity, speed, and transparency demanded by the global PCT system.

Another critical procedural challenge is the multiplicity of forms, fee structures, and timelines that do not always align seamlessly between Indian domestic procedures and the PCT framework. Innovators often face confusion or delays when transitioning from the international phase to the national phase of patent filing. Small and medium enterprises (SMEs), individual inventors, and start-ups—who are vital to India's innovation ecosystem—often lack the financial and technical resources to navigate the complex web of compliance with both IPA and PCT systems. Without targeted support, harmonization risks remaining a theoretical goal rather than a practical reality.

Economically, harmonization with the PCT raises important questions about accessibility and affordability of patented goods, particularly in sectors such as pharmaceuticals, biotechnology, and agriculture. India's developmental priorities demand that patents do not become instruments of market monopoly that deny essential commodities to the poor. While the PCT facilitates global patent protection, it may also indirectly promote the consolidation of intellectual property rights in the hands of large multinational corporations. For a country like India, where a large portion of the population lives below the poverty line and where public healthcare is largely subsidized, over-harmonization could exacerbate social and economic inequalities. Therefore, economic prudence must guide the harmonization process to ensure that it complements rather than conflicts with national goals.

Further complicating the picture are the administrative challenges, which include the lack of coordination between various ministries, inadequate financial allocation for IP infrastructure, and limited awareness among stakeholders. Despite the launch of the National IPR Policy in

2016, which outlined objectives for promoting innovation and strengthening the IP regime, ground-level implementation has often lagged. Inter-departmental coordination—especially between the Department for Promotion of Industry and Internal Trade (DPIIT), Indian Patent Office, Ministry of Health, and academic institutions—remains suboptimal. Harmonization with PCT processes requires a coordinated national strategy where all stakeholders operate in unison towards shared goals.

One of the most persistent challenges in harmonization lies in the tension between national sovereignty and global standardization. While the PCT promotes a uniform and predictable global patent system, countries like India insist on retaining policy space to address unique national challenges. For example, compulsory licensing, which is permitted under the Indian Patent Act for ensuring access to essential medicines, is rarely invoked in countries that follow stricter PCT-aligned rules. India's use of such flexibilities has been a point of contention in international forums, often drawing criticism from multinational pharmaceutical giants and their home countries. Nevertheless, these flexibilities are critical tools in India's legal arsenal for achieving public interest objectives, and any attempt at harmonization must preserve this autonomy.

The comparative analysis with other developing economies like Brazil, South Africa, and China further reinforces the fact that harmonization is not a one-size-fits-all endeavor. These countries have adopted unique approaches to balancing international obligations with domestic needs. China, for example, has rapidly modernized its IP infrastructure while offering subsidies and incentives to local patent filers. Brazil has taken a stand against pharmaceutical evergreening, while South Africa has emphasized transparency and public consultation in patent law reform. India can learn from these models while crafting a harmonization strategy that is both context-sensitive and globally relevant.

The Indian judiciary has also played a pivotal role in shaping the contours of harmonization. Landmark decisions such as *Novartis AG v. Union of India*, *Bayer v. Natco*, and *Roche v. Cipla* have laid down principles that protect public interest while interpreting the patent law in light of international obligations. These rulings demonstrate that harmonization is not merely a legislative or administrative process but also a matter of jurisprudential evolution. The courts have repeatedly asserted the importance of balancing innovation incentives with public access, thus providing a blueprint for navigating the PCT integration in a way that does

not undermine constitutional values.

However, harmonization is not an end in itself. It is a means to improve access to innovation, enhance the credibility of the patent system, and foster international cooperation in technology development. For India, the path forward lies in adopting a calibrated approach to harmonization—one that respects global standards but does not compromise on national interest. This requires continuous dialogue with international bodies like WIPO, active participation in global IPR debates, and the assertion of India's position as a leader among emerging economies.

The future of harmonization also depends on educating stakeholders. Inventors, startups, universities, and even legal professionals need to be trained on how the PCT system works and how it can be effectively leveraged. Lack of awareness leads to underutilization of global patenting opportunities. Government-led initiatives, in collaboration with private sector and academic institutions, must aim to demystify the process of international patent filing through workshops, webinars, and handholding programs.

Another important aspect of harmonization is the financial support required to make it accessible. Many Indian innovators, particularly those in academia or rural industries, are deterred by the high cost of international filings. The PCT route, while streamlined, involves significant expenses in translations, attorney fees, and maintenance costs in multiple countries. Without robust financial assistance mechanisms such as grants, subsidies, patent vouchers, or soft loans, harmonization will benefit only a narrow elite. Thus, government policies must ensure that cost is not a barrier to global participation in the patent system.

Technology can also act as a harmonizing force. The use of digital platforms, artificial intelligence, and cloud-based systems in patent application, examination, and monitoring can bridge gaps between domestic and international procedures. By investing in technological upgradation of the Indian patent ecosystem, harmonization with the digitally advanced PCT system becomes more feasible and less resource-intensive.

Finally, harmonization with the PCT must align with the broader goal of making India an innovation hub. As India aspires to be a $5 trillion economy, intellectual property will be at the heart of its growth story. An IPR system that is aligned with global norms yet grounded in

domestic realities will ensure that Indian innovations are not just protected but also respected globally. This requires political will, legal agility, administrative efficiency, and most importantly, a vision that places innovation at the center of national development.

The harmonization of the Indian Patent Act with the Patent Cooperation Treaty is not a binary issue but a dynamic and evolving process. It requires careful navigation through competing interests—public vs. private, national vs. international, economic vs. ethical. While challenges abound, they are not insurmountable. With the right mix of policy foresight, legal reform, stakeholder engagement, and international collaboration, India can harmonize its patent law with the PCT in a manner that strengthens its innovation landscape without compromising its constitutional and developmental commitments.

"Recommendations and Legal Reforms for IPR: Including Financial Assistance Mechanisms for Indian Innovations"

1. Strengthening IPR Infrastructure

India's existing IPR infrastructure—comprising patent offices, trademarks registries, and IP Appellate Boards—must be modernized to meet global standards. Patent examiners often face overwhelming workloads, resulting in delayed processing. To counter this, the following reforms are recommended:

Increase manpower and training: Recruit more technically qualified patent examiners and trademark officers. Regular training must be conducted to keep them updated with technological and legal developments.

Digitization and AI integration: Digitizing records and incorporating AI tools for prior-art search and document management can drastically cut processing time.

Regional IP Cells: Establishing IPR facilitation centers across the country, particularly in tier 2 and tier 3 cities, would decentralize access and empower local innovators.

2. Legal Reforms to Promote Ease of Filing

The current legal process of registering intellectual property in India can be tedious, especially for first-time applicants and small innovators. Legal reforms must aim at:

Simplified procedures: Reduce bureaucratic red tape and streamline application processes for patents, trademarks, designs, and copyrights.

Single-window systems: Establish unified online portals where innovators can file, monitor, and respond to IPR applications.

Fast-track options: Expand the scope of expedited examination processes beyond start-ups to include universities and government-funded R&D bodies.

3. Stronger Enforcement and Adjudication Mechanisms

Enforcement of IPR remains a major hurdle in India. Counterfeiting, piracy, and patent infringement are rampant, causing significant losses to genuine right holders. Policy recommendations in this area include:

Establishment of dedicated IPR courts: Specialized IPR benches within high courts can ensure expert adjudication and quicker resolution.

Strengthening the Copyright Board and IP Appellate Authorities: Clear demarcation of powers and regular appointments of technical members are vital for efficient functioning.

Capacity-building for law enforcement: Police and customs officials must be sensitized and trained to handle IP-related offences.

4. Promoting Domestic Innovation and IP Generation

One of the core challenges India faces is the relatively low number of domestic patent filings compared to global players. To stimulate domestic innovation:

University and institutional IP policies: Encourage academic institutions to create IP policies that reward faculty and students for filing patents.

Mandatory IP audits in research funding: Government-funded R&D should be tied to compulsory patenting and commercialization milestones.

Recognition and incentives: Annual national awards for patent filers, researchers, and institutions with high IP output will inspire participation.

5. Tailoring the Patent Act for Contemporary Needs

The Indian Patent Act, 1970 has undergone several amendments to align with TRIPS and other global obligations. However, further refinements are required:

Clarification of Section 3(d): While this section protects against "evergreening" of patents, it also creates ambiguity for pharmaceutical innovations. Clear guidelines can prevent misuse while safeguarding innovation.

Introduce Utility Models: Similar to the German "Gebrauchsmuster" system, utility models or petty patents could be granted for incremental innovations, especially from MSMEs and rural inventors.

Improve compulsory licensing framework: Streamline the procedure for issuing compulsory licenses while ensuring transparency and international compliance.

6. Financial Assistance Mechanisms for Innovators

Many Indian innovators, particularly from MSMEs, academia, and rural sectors, struggle with the financial burden of patent filing, prosecution, and maintenance. Dedicated financial support systems must be implemented to overcome this gap.

a. Government Subsidies and Grants

Patent filing reimbursement: Expand schemes like the Start-up Intellectual Property Protection (SIPP) to include more sectors and provide full reimbursement for domestic and international filings.

Patent prosecution assistance: Offer grants for covering legal fees, patent translation, and opposition procedures.

Innovation vouchers: Introduce vouchers that innovators can redeem with accredited IP service providers for services such as patent drafting and landscape analysis.

b. Low-interest IP Loans and Credit Lines

Dedicated IP-backed loan schemes: Financial institutions should recognize IP as a valuable asset and provide collateral-free loans against IP holdings.

Credit guarantee for MSMEs: The government could act as a guarantor for loans taken by MSMEs to file and protect intellectual property.

c. Tax Incentives

Tax deduction on IP creation: Provide weighted deductions for R&D expenditure, including patent filing and maintenance costs.

Royalty taxation reforms: Reduce the tax rate on royalties earned from patented inventions to encourage monetization.

7. Public-Private Partnerships (PPP) in IP Ecosystem

Leveraging private sector expertise is essential for building an agile and responsive IP ecosystem. Through PPPs:

IPR facilitation centers: Jointly run by government and industry bodies, these centers can offer end-to-end support to innovators, from ideation to commercialization.

IP clinics in universities: Law firms and corporate IP teams can conduct clinics to help students and researchers with patent searches and filings.

Collaborative patent pools: Industry-led patent pools can encourage cross-licensing and reduce litigation costs.

8. Enhancing IP Awareness and Education

A long-term IPR policy must be grounded in spreading awareness and building a culture of innovation. Recommendations include:

Inclusion in school and college curriculum: Introduce IPR concepts at an early stage to foster appreciation for innovation and originality.

IP literacy programs: Conduct region-specific IP awareness drives in vernacular languages targeting artisans, rural innovators, and small businesses.

Judicial and administrative training: Regular workshops for judges, patent examiners, and bureaucrats on evolving global IP norms and challenges.

9. International Collaboration and Harmonization

To remain competitive in global trade, India must proactively engage in shaping and harmonizing IP policies with international standards:

Strengthen role in WIPO and WTO: India must actively participate in negotiations that protect public interest while advocating for flexibilities in IP agreements.

Bilateral treaties on IPR cooperation: Engage in treaties with like-minded countries to share patent databases, best practices, and capacity-building programs.

Global IP dispute resolution: India must prepare institutions to handle international IP disputes through arbitration or transnational litigation.

10. Fostering IP Commercialization and Technology Transfer

Patent filings alone do not translate to economic gains. Commercialization is key. For this:

National IP commercialization platform: Establish a central platform connecting IP holders with industries, venture capitalists, and licensing agents.

Technology Transfer Offices (TTOs): Universities and research centers should be equipped with TTOs that help patent, license, and commercialize innovations.

Industry-academia collaboration: Offer tax breaks and recognition for industries that adopt or invest in patented university technologies.

11. Supporting Traditional Knowledge and Grassroots Innovations

India's rich pool of traditional knowledge (TK) and grassroots innovations often remains unprotected. Legal and policy mechanisms should ensure:

Expansion of TK Digital Library: Continued documentation and digitization of TK in multiple languages to prevent biopiracy.

Geographical Indication (GI) promotion: Offer marketing support to GI holders and train them in enforcing their rights.

Protection of community rights: Enable community-based ownership models for patents and trademarks related to tribal or rural innovations.

12. Monitoring, Evaluation and Accountability

Policy without effective implementation loses value. Therefore:

Annual IPR impact audits: Independent agencies must review the socio-economic impact of IPR policies, schemes, and expenditures.

IPR dashboard: A real-time monitoring dashboard displaying IPR applications, grants, pendency, and commercialization status can improve transparency.

Accountability for delays: Fixed timelines and penalties for procedural delays in IPR offices can ensure greater efficiency.

A comprehensive IPR regime must not only protect rights but also promote creativity, encourage research, and ensure fair public access. While India has taken commendable steps in IPR policy making—especially with the National IPR Policy of 2016—there remains considerable scope for improvement. By adopting global best practices and focusing on inclusivity, financial assistance, legal reforms, and commercialization strategies, India can

unlock the full potential of its innovation ecosystem. The proposed policy recommendations and legal reforms outlined here aim to transform India from a knowledge-consuming economy to a knowledge-producing powerhouse.

BIBLIOGRAPHY

Academic Journals and Articles

1. **Ritu Sharma**, "Harmonizing Indian Patent Law with the Patent Cooperation Treaty: A Legal Analysis," *Indian Journal of Intellectual Property Law*, 2022.
   Link
2. **S. Banerjee**, "Patent Law Reforms and Global Compliance: Challenges in India," *Journal of World Intellectual Property*, 2023.
   https://onlinelibrary.wiley.com/journal/17471796
3. **R.K. Menon**, "Patent Cooperation Treaty and the Indian Dilemma: A Critical Review," *National Law Review*, 2024.
   https://www.natlawreview.com/
4. **N. Choudhury**, "India and the PCT: Compliance, Constraints, and Future Scope," *NLU Delhi Journal of Legal Studies*, 2022.
   https://nludelhi.ac.in/
5. **P. Srivastava**, "A Comparative Analysis of PCT Compliance: India vs Global Standards," *NUJS Law Review*, Volume 16, Issue 2, 2023.
   https://www.nujs.edu/law-review/
6. **WIPO Journal**, "Developing Countries and the PCT: Bridging the Gap," *WIPO Magazine*, 2022.
   https://www.wipo.int/wipo_magazine/en/
7. **NALSAR Law Review**, "India and Global Patent Regime: Bridging the Gap," Volume 18, Issue 1, 2024.
   https://nalsar.ac.in/research-publications

🕮 Books

1. **Dr. V. Ramaswamy**, *Patent Law in India: A Critical Commentary*, LexisNexis, 2021.
   https://www.lexisnexis.in/
2. **Meenakshi Rajput**, *Intellectual Property Rights: Global Perspective and India's Position*, Eastern Book Company, 2022.
   https://www.ebcwebstore.com/
3. **R. Ahuja**, *Understanding Patent Law and Innovation Policy*, Universal Law Publishing, 2020.
   https://www.unilawpub.com/
4. **S. Mishra**, *The Future of Patent Harmonisation: Comparative Global Analysis*, Routledge, 2023.
   https://www.routledge.com/
5. **Aarti Singh**, *Intellectual Property: National and International Dimensions*, Cambridge University Press, 2023.
   https://www.cambridge.org/

🗎 Reports

1. **World Intellectual Property Organization (WIPO)**, "The Patent Cooperation Treaty: A User's Guide," 2022.
   https://www.wipo.int/pct/en/
2. **NITI Aayog**, "Strengthening IP Ecosystem in India: Harmonizing with International Norms," 2023.
   https://www.niti.gov.in/
3. **Centre for Innovation, IP and Competition**, "India's Patent Law and Global Commitments: Challenges and Recommendations," 2024.
   https://ciipc.org/
4. **Department for Promotion of Industry and Internal Trade (DPIIT)**, "India's IPR Policy Report," 2023.
   https://dpiit.gov.in/
5. **United Nations Development Programme (UNDP)**, "Innovation and IP Systems in Emerging Economies: India Case Study," 2022.
   https://www.undp.org/

🌐 Online Articles and Blogs

1. **SpicyIP**, “Is India Ready for Full PCT Integration?” 2023. https://spicyip.com/
2. **IPKat**, “Indian Patent Act and PCT: Still Miles to Go,” 2022. https://ipkitten.blogspot.com/
3. **Bar & Bench**, “Legal Challenges in Harmonizing Patent Laws with Global Treaties,” 2024. https://www.barandbench.com/
4. **IndiaCorpLaw Blog**, “Patent Harmonisation and Indian Policy: A Crossroad,” 2023. https://indiacorplaw.in/
5. **LegalServiceIndia**, “Research Outline on India's International IP Compliance,” 2023. https://www.legalserviceindia.com/
6. **WIPO News**, “India’s Journey Towards IP Harmonisation: A Timeline,” 2022. https://www.wipo.int/news/en/

Legislative and Policy Documents Referenced

1. The Patents Act, 1970 (as amended in 1999, 2002, and 2005)
2. Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), 1995
3. National IPR Policy, 2016 – Department for Promotion of Industry and Internal Trade (DPIIT)

Case Laws Studied

1. *Novartis AG v. Union of India*, (2013) 6 SCC 1
2. *Natco Pharma Ltd. v. Bayer Corporation*, Compulsory License Order, 2012
3. *Roche v. Cipla*, Delhi High Court, 2009

D. Country Case Studies

Brazil

- Industrial Property Law, 1996

- Role of ANVISA in pharmaceutical patenting
- Compulsory Licensing of Efavirenz, 2007
- Resistance to TRIPS-plus provisions in bilateral FTAs

South Africa

- Intellectual Property Policy Phase I (2018)
- Lack of substantive examination and reforms proposed

- Case studies involving evergreening practices and their policy response